Smoking and SARS-CoV-2 Impair Dendritic Cells and Regulate DC-SIGN

Expression in Tissues

Guoshuai Cai^{1*}, Yohan Bossé², Mulong Du^{3,4}, Helmut Albrecht⁵, Fei Qin⁶, Xuanxuan Yu⁶, Xizhi Luo⁶, Michelle Androulakis^{7,8}, Xia Zhu¹, Jun Zhou¹, Xiang Cui¹, Changhua Yi⁹, Chao Cheng¹⁰, Mitzi Nagarkatti¹¹, Prakash Nagarkatti¹¹, David Christiani^{3,12}, Michael Whitfield¹³, Christopher Amos¹⁰, Feifei Xiao^{4*}

¹Department of Environmental Health Sciences, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA

²Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ), Department of Molecular Medicine, Laval University, Quebec City, Canada

³Departments of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts

⁴Department of Biostatistics, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China

⁵Department of Internal Medicine, Prisma Health Medical Group, University of South Carolina, Columbia, SC, USA

⁶Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA

⁷Neurology, Columbia VA Health System, Columbia, SC, USA

⁸Department of Neurology, School of Medicine, University of South Carolina, Columbia, SC, USA

⁹Nanjing Clinical Medical Center for Infectious Diseases, the Second Hospital of Nanjing, Southeast University, Nanjing, China.

¹⁰Institute for Clinical and Translational Research and Dan L. Duncan Comprehensive Cancer Center, Department of Medicine, Baylor College of Medicine, Houston, TX, USA

¹¹Department of Pathology, Microbiology and Immunology, School of Medicine, University of South Carolina, Columbia, USA.

¹²Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts

¹³Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA.

*Address correspondence to:

Guoshuai Cai

Department of Environmental Health Sciences

Arnold School of Public Health

University of South Carolina

915 Greene Street

Discovery 517

Columbia, SC 29204

GCAI@mailbox.sc.edu

Phone: 803-777-4120

Feifei Xiao

Department of Epidemiology and Biostatistics

Arnold School of Public Health

University of South Carolina

915 Greene Street

Discovery 449

Columbia, SC 29204

XIAOF@mailbox.sc.edu

Phone: 803-777-8936

Graphical Abstract

1 Smoking effect, compared to healthy control

Effects of smoking and SARS-CoV-2 on respiratory immune system

3 Mild COVID-19, compared to healthy control

4 Severe COVID-19, compared to moderate cases

Highlights

Smoking upregulates the expression of *ACE2* and *CD209* and inhibits DC maturation in lungs.

SARS-CoV-2 modulates the DCs proportion and *CD209* expression differently in lung and blood.

Severe infection is characterized by DCs less capable of maturation, antigen presentation and MHCII expression.

DCs shift from cDCs to pDCs with SARS-CoV-2 infection but are trapped in an immature stage in severe cases.

Summary

The current spreading novel coronavirus SARS-CoV-2 is highly infectious and pathogenic. In this study, we screened the gene expression of three SARS-CoV-2 host receptors (ACE2, DC-SIGN and L-SIGN) and DC status in bulk and single cell transcriptomic datasets of upper airway, lung or blood of smokers, non-smokers and COVID-19 patients. We found smoking increased DC-SIGN gene expression and inhibited DC maturation and its ability of T cell stimulation. In COVID-19, DC-SIGN gene expression was interestingly decreased in lung DCs but increased in blood DCs. Strikingly, DCs shifted from cDCs to pDCs in COVID-19, but the shift was trapped in an immature stage (CD22⁺ or ANXA1⁺ DC) with MHCII downregulation in severe cases. This observation indicates that DCs in severe cases stimulate innate immune responses but fail to specifically recognize SARS-CoV-2. Our study provides insights into smoking effect on COVID-19 risk and the profound modulation of DC function in severe COVID-19.

Key words

ACE2, DC-SIGN, smoking, COVID-19, dendritic cells

Introduction

In 2020, a novel coronavirus SARS-CoV-2 has been spreading as a pandemic infection. SARS-CoV-2 is highly infectious and pathogenic through human-to-human transmission and causes severe Coronavirus Disease 2019 (COVID-19)¹. COVID-19 critical cases are often characterized by a pro-inflammatory “cytokine storm” with a release of excessive cytokines

(including IL-6, IL-1, IL-2, IL-10, TNF- α and IFN- γ and others) and a hyperactive immune response which cause damage to target organs. Despite extensive research, the exact immune pathophysiology of SARS-CoV-2 has remained elusive.

Coronavirus is a single-stranded RNA virus that can be divided into four main genres including the alpha, beta, gamma and delta coronaviruses². Studies showed that SARS-CoV-2 is closely related to SARS-CoV, with around 80% homology of genome³, belonging to the same β -genus⁴, having similar receptor-binding domain (RBD) structures² and causing similar clinical symptoms including acute respiratory response⁵. Many viruses are capable of using alternative receptors to enter host cells. This is also true for SARS coronavirus. Three receptors—ACE2, DC-SIGN and L-SIGN (gene symbol as *ACE2*, *CD209* and *CLEC4M* respectively) have been found to be involved in the pathogenicity of SARS-CoV⁶⁻⁸. ACE2 was also been quickly confirmed to be the receptor for SARS-CoV-2⁹. Recently, DC-SIGN and L-SIGN were identified as alternative receptors for mediating SARS-CoV-2 entry into human cells¹⁰.

In vivo, L-SIGN is largely expressed on endothelial cells in liver sinusoids and lymph nodes, whereas DC-SIGN is mainly expressed on dendritic cells (DCs)¹¹. Aside from epithelial cells, SARS-CoV infection was found in T cells, macrophages (M ϕ) and monocyte-derived dendritic cells and this viral attack is probably responsible for the lymphopenia which was commonly observed in patients with SARS-CoV infection¹². While DC-SIGN and L-SIGN provide gateways for SARS coronavirus to attack infected immune cells, they play important anti-viral roles. They both capture, transmit and disseminate virus within the host^{13,14}. With the dual roles of DC-SIGN as a SARS-CoV-2 gateway and an innate immune initiator, DCs may play an important and complicated role in OVID-19 patients and link to clinical phenotypes. Studies indicate a decrease of conventional DCs (cDC) and plasmacytoid DCs (pDC) in the lung and blood of severe COVID-19 cases^{15,16}. Yet, comprehensive insights into modulation of DCs in tissues with COVID-19 are still missing.

Environmental exposures might influence the COVID-19 risk by regulating receptors and remodel immune cells. The clinical epidemiology data showing a higher risk of smokers of developing a severe COVID-19 disease¹⁷. In agreement with that, we previously demonstrated an upregulation of ACE2 in the lungs of smokers¹⁸. In this study, we further investigated the effects of smoking on the gene expression of the two newly identified SARS-CoV-2 receptors DC-SIGN and L-SIGN by analyzing large-scale bulk tissue datasets and high-granularity single cell datasets of normal lung tissues. Also, we systematically studied the transcriptome dysregulation in single cells in the upper airway (nasopharynx/pharynx samples), lower airway (bronchoalveolar lavage fluid (BALF) samples) and peripheral blood (peripheral blood mononuclear cell (PMBC) samples) of COVID-19 patients. These single cell datasets enabled the investigation of variation of DC activation in smokers and non-smokers, as well as mild and severe COVID-19 and healthy controls. In severe COVID-19, we found significantly decreased DCs and its shift to immature subsets. The results illustrate the pathogenicity and virulence of SARS-CoV-2 infection from the aspect of DCs which is a critical player in the immune response to viral infection.

Results

Infection correlation and variation of immune factors in COVID-19 upper airway.

In the nasopharynx/pharynx samples of 238 patients with acute respiratory illnesses (ARIs), we found ACE2 ($P = 3.9 \times 10^{-10}$) and DC-SIGN ($P = 0.048$) gene expression were significantly higher with the SARS-CoV-2 infection (Fig. S1). In addition, we found ACE2 gene expression was strongly positively associated with the viral load of SARS-CoV-2 ($P = 5.3 \times 10^{-4}$). No data was available for *CLEC4M*. Notably, the gene expression of essential factors of antigen-presenting cells (APC) for antigen presentation including CD40, CD80 and CD86, HLA genes, IgG immunoglobulin receptor (FcR) III and interferon-gamma (IFN- γ) were upregulated in SARS-

CoV-2 ARIs compared to non-viral ARIs, whereas IgA and IgE FcRs, interferon-kappa (IFN- κ), and cyclooxygenase (COX) genes *PTGS1* and *ALOS5* were downregulated. The gene expression of *ACE2*, *CD80*, *CD86*, *CD83*, IFN- γ , *FCER1G* and IgG FcRs were increasingly associated with the viral load of SARS-CoV-2 (Fig. 1A, Fig. S1). No such association were observed in HLA genes. In addition, the proportions of activated CD4⁺ memory T cells (CD4m T) and M1 M ϕ were increased in SARS-CoV-2 ARIs and significantly associated with increased viral load (Fig. 1A, Fig. S1), while the proportions of activated mast cells and neutrophils were decreased. The proportions of these 4 cell types and the active DC well predicted the SARS-CoV-2 load ($\rho = 0.79$, $P = 1.3 \times 10^{-7}$, Fig. 1A) and discriminated between non-viral and SARS-CoV-2 ARIs ($P = 1.2 \times 10^{-5}$, Fig. S1).

Interestingly in ARIs with a significant SARS-CoV-2 viral load ($\log_{10}$ CPM > 1), we observed distinct subtypes associated with activation of DCs and T/M ϕ cells (Fig. 1B). According to the activation of specific immune cell types, we further classified ARIs into four subtypes DC+ and T/M ϕ +, Neu+ and DC-T/M ϕ -Neu- (Fig. 1B). The DC+ subtype was characterized with activated DCs, downregulated FcRs and HLA genes. The T/M ϕ + subtype was characterized with activated T or M ϕ , upregulated viral gateway *ACE2* and *CD209* as well as immune factors including *INFG*, *CD86*, *FCGR3A*, *FCGR1G* and HLA genes. The Neu+ subtype was characterized with enriched neutrophils, upregulated FcRs genes and Cox genes (*PTGS2* and *ALOS5*), and downregulated HLA genes and *ACE2*. The DC-T/M ϕ -Neu- subtype was characterized with downregulated FcRs genes, *ACE2* and *CD209*. These results provide new clues for the variation of immune response in COVID patients with its potential link to the activation of specific immune cell types. Not like the T/M ϕ + subtype with activated immune factors and high expression of *ACE2* and *CD209*, DC+, Neu+ and DC-T/M ϕ -Neu- subtypes may produce high virus load by immunodeficiency.

DC-SIGN is associated with COVID-19 severity, immune- and neural-related phenotypes and respiratory diseases

We investigated the association of the expression of ACE2, DC-SIGN and L-SIGN with COVID-19 risk by large-scale population genetic association analyses (see Methods). Using Mendelian Randomization (MR), we found that the expression of DC-SIGN plasma protein were associated with increased COVID-19 risk ($\beta = -0.14, P = 3.39 \times 10^{-3}$) and severity ($\beta = -0.30, P = 5.41 \times 10^{-5}$; Table S1). Such significant associations were not found in ACE2 and L-SIGN.

The important role of DC-SIGN in phagocytosis and immune activation was also reflected by the phenotype associations detected in this study. GWAS found that the genetic variation of *CD209* is associated with multiple diseases, including asthma (the top among detected associations, $P = 1.0 \times 10^{-13}$), cancers and neurological disorders (Table S2), showing the possible underlying links involving by DCs and/or Mø. Neurological symptomatology associated with COVID-19 includes headaches, confusion, hyposmia, encephalitis, myelitis, neuropathy, and stroke^{19,20}. Given circulating DCs in cerebrospinal fluid are capable of reaching cervical lymph nodes outside central nervous system (CNS)²¹, our data suggests DCs is a possible route for SARS-CoV-2 infection in the brain, which also provides a new explanation to the neurotropism of SARS-CoV-2²². Moreover, the transcriptome-based PheWAS analysis found that *CD209* gene expression is significantly associated with the immune cell composition, including the depletion of neutrophils (count: $\beta = -0.10, P = 4.0 \times 10^{-5}$; percentage: $\beta = -0.60, P = 3.2 \times 10^{-5}$) and overall WBC (count: $z = -3.34, P = 8.3 \times 10^{-4}$), as well as the augmentation of lymphocytes (percentage: $\beta = 0.14, P = 3.00 \times 10^{-4}$) and monocytes (percentage: $\beta = 0.15, P = 1.24 \times 10^{-3}$) in lung (Table S3). These associations were further confirmed by MR analysis on DC-SIGN plasma protein expression (neutrophil count: $\beta = -0.03, P = 1.38 \times 10^{-16}$; neutrophil percentage: $\beta = -0.02, P = 0.02$; WBC count: $\beta = -0.03, P = 5.40 \times 10^{-27}$; lymphocyte percentage: $\beta = 0.02, P = 5.29 \times 10^{-5}$; monocyte

percentage: $\beta = 0.03$, $P = 8.52 \times 10^{-3}$; Table S4). Moreover, we also observed such significant associations of *CD209* expression with immune cell composition in blood samples of 160 ARDS cases and 142 non-ARDS controls, regardless of the disease status (Fig. S2). In addition, we found that *CD209* expression was associated with immune related symptoms such as tiredness or low energy, depression and duration of fitness (Table S3). In lung adenocarcinoma tumors, we only observed a slight downregulation of *CD209* ($\beta = -0.26$, $P = 0.07$) and no significant association with survival ($P = 0.33$) and tumor stage ($P = 0.80$).

Smoking upregulates the expression and decreases the methylation of *CD209* in lungs.

We previously have found that smoking upregulates the lung expression of *ACE2*¹⁸. In this study, we further investigated the effect of smoking on expression of *CD209* and *CLEC4M* from 8 independent studies (N=1162). Adjusted for age and sex, *CD209* expression was significantly upregulated in smoker lungs (meta-analysis $\beta = 0.15$, $P = 1.1 \times 10^{-4}$, Fig. 2A). Significant association (meta-analysis $\beta = 0.1$, $P = 0.03$) between *CD209* expression and smoking status (never-, former- and current- smoker) was also observed with 4 out of 5 available datasets showing a positive trend of association (Fig. 2A). We did not find a significant difference in *CLEC4M* gene expression (Fig. S3).

We next investigated the dysregulation of *ACE2*, *CD209* and *CLEC4M* in specific types of cells in normal airway samples of never-smokers and ever-smokers. Cell types were identified from scRNA-seq datasets of bronchial epithelium (GSE131391) and lung tissues (GSE122960 and Madisson) using known markers (Fig. S4, Fig. S5). We found that *ACE2* was mainly expressed in pneumocytes, secretory cells, ciliated cells, never-smokers' club cells and smokers' goblet cells (Fig. 2B), which was consistent with the recent study of Ziegler et al.²³ and our previous observation¹⁸. Compared to never-smokers, we found higher detection rate of *ACE2* in ciliated cells in ever-smokers in both lung datasets. The GSE122960 dataset also

showed higher expression of *ACE2* in AT1 and fibroblast cells by smoking. Active expression of *CD209* was found in lung DCs, Mø and monocytes (Fig. 2B). Compared to non-smokers, ever-smokers showed increased *CD209* expression in lung DCs (GSE122960 $P < 0.01$ and Madisson $P < 0.01$). Higher *CD209* expression was also found in Mø of ever-smokers in the dataset of GSE122960 ($P < 0.001$). The expression of *CLEC4M* was only notably detected in lung vessel epithelial cells and no significant smoking effect was observed.

Further, we investigated smoking effect on gene methylation of *CD209* and *ACE2* by comparing DNA methylation data from smoker and non-smoker lungs in 5 studies (N = 242). Adjusted by age and sex, an overall decrease of methylation was detected across *CD209* in smokers, including two significant loci (cg01618851, cg07608333) by meta-analysis and two significant loci (cg04015765, cg21848746) in the GSE133062 study (Fig. 2C). Although not significant with limited sample size, loci cg01618851 and cg07608333 showed trends of negative correlation between *CD209* gene expression and methylation (Fig. 2C). No data was available to investigate the expression-methylation association for loci cg04015765 and cg21848746. In addition, no significant association was observed in *ACE2* (Fig. S6).

Smoking modulates the function of lung DCs

To verify whether smoking affects the composition of immune cells in lung, we assessed immune cell proportions in normal lung tissues from the above 8 independent bulk transcriptomics studies and evaluated their associations with smoking by meta-analysis. Among 22 immune cell types, we found that resting DCs, CD8⁺ T cells, and activated CD4m T cells were augmented while resting CD4m T cells, activated NK cells, M1 Mø, eosinophils and neutrophils were depleted in lungs of smokers (Fig. 3A left). A similar pattern of associations with smoking history (never, former or current smoker) was observed, with significant positive correlation for CD8 T cells and follicular helper T cells, and negative correlation for CD4 memory resting T cells, activated NK cells, eosinophils and neutrophils (Fig. 3A right). In addition, both

resting and activated DCs showed trends of positive association with the smoking history. A trend of increase of DC proportion in smokers was also found in scRNA-seq datasets (Fig. S7).

Further, we investigated whether smoking affects the maturation of DCs by examining the gene expression of the maturation marker *CD83* and the T-cell stimulatory molecules *CD86*, *CD80* and *CD40* in the GSE122960 and Madissoon scRNA-seq datasets (Fig. 3B). In DCs of ever-smoker lungs, we found a significant downregulation of *CD83* in both datasets. In the Madissoon dataset, we also found significantly lowered expression of *CD40* and *CD80*. These observations indicate that smoking inhibits both maturation and T cell stimulation ability of DCs, although *CD86* was upregulated in the Madissoon dataset. Pathway analysis also showed that smoking inhibited viral detection and DC maturation including signaling pathways of T cell receptor, B cell receptor, Toll-like receptor (TLR) and RIG-I-like receptor (RLR), as well as pathways involved in *Vibrio cholerae* and *Escherichia coli* infections (Fig. 3C). Interestingly, smoker lung DCs also showed upregulated pathways which are involved in immune responses, including antigen processing and presentation, cytokine-cytokine receptor interaction, asthma (Fig. 3D), graft versus host disease and others. In addition, smoking inhibited DNA replication (Fig. 3D), cell cycle, metabolism and DNA repair related pathways, and invoked detoxification processes.

SARS-CoV-2 modulates the function of DCs and *CD209* expression

We next systematically investigated the cell type-specific expression of *CD209* in upper airway, lower airway and peripheral blood by analyzing scRNA-seq datasets from one nasopharynx/pharynx, one BALF and two PBMC (Lee et al., Wilk et al.) studies from COVID-19 patients and healthy controls. Cell types were identified in each dataset (Fig. S8), and the detection rates and average expression of *ACE2*, *CD209* and *CLEC4M* were compared between groups (Fig. 4A). Compared to healthy controls, patients with mild and severe disease showed higher detection rates of *ACE2* in the nasopharynx/pharynx secretory, ciliated, and

pulmonary epithelial cells. No notable expression of *CLEC4M* was observed in any cell type in any of the four datasets.

Notable expression of CD209 was found in DCs, airway Mø and blood monocytes (Fig. 4A). Significantly, we found that *CD209* expression in lung monocyte-derived macrophages (MoD Mø) and blood classical (CD16⁻ or CD14⁺) monocytes was severity-dependently decreased in COVID-19, while CD16⁺ monocytes showed a severity-dependent increase of *CD209* expression in the dataset of Wilk et al. In DCs, *CD209* expression was decreased in lungs but increased in blood of COVID-19 cases, as compared to healthy controls. With a small number of detected DCs (N = 12), the Lee PBMC dataset didn't detect such increase in severe COVID-19 cases. The discrepancy among anatomical sites were also found in the alteration of the DC proportion among white blood cells (WBC) (Fig. 4B). In airway samples, the proportion of DCs was increased in mild cases and decreased in severe cases. A decrease was also found in severe cases in blood, but no notable change was observed in mild cases. Inversely to DCs, the proportions of MoD Mø and monocytes were increased in severe cases in all three tissues. These observations may indicate a site-specific impact of COVID-19 on the differentiation of monocytes to DCs and Mø.

We further identified transcriptome-wide differently expressed genes (DEGs) and signaling pathways in DCs in COVID-19 lung and blood (Fig. 5). Compared to healthy controls, an extensive transcriptomic change was found in lung, with expression of 184 DEGs (93 for mild; 91 for severe, Fig. 5A) changed more than 2-fold, whereas only 15 (8 for mild; 11 for severe, Fig. 5B) were detected in blood. Relatedly, we also found a broad COVID-19 severity-associated activation of viral detection and immune stimulation (cytokine-cytokine receptor interaction, cytosolic DNA sensing, TLR, Nod-like receptor (NLR), chemokine signaling, B cell receptor signaling and Mark signaling) in lung, while only mild immune stimulation (cytokine-cytokine receptor interaction and cytosolic DNA sensing) was found in blood. In both lung and blood, immune response related pathways (graft versus host disease, viral myocarditis,

Leishmania infection and others) were activated in mild cases as compared to healthy control but interestingly were inhibited in severe cases as compared to mild cases. Such pattern was also observed on antigen processing and presentation, host metabolism as well as DNA replication in lung but not in blood. Correspondingly, immune initiation related genes (including *CD1A*, *CD1C*, *CD1E*, *CCL17*, *FCER1A*, *FCGR2B* and others) and ribosome genes were significantly downregulated in severe COVID-19 cases as compared to healthy controls, whereas inflammatory signals (including interferon genes, *CCL2*, *CCL4*, *CCL8* and others) were upregulated (Fig. 5C). Compared to mild cases, chemokines (including *CCL2*, *CCL4*, *CCL8*) and MAPK substrates (including *JUN*, *USF1*, *FOS*) were upregulated in severe cases, whereas antigen presentation related genes (*HLA-DQA2*, *C1QC* and *C1QA*) were downregulated. Interestingly in blood, we also found neural disease related pathways were severity-dependently activated and cancer related pathways were inhibited in severe cases (Fig. 5B), which may link to the neurologic and other clinical manifestations of COVID-19.

The expression of the maturation marker (*CD83*), T-cell stimulation molecules (*CD40*, *CD80*, *CD86*) and antigen presentation molecules (*HLA-DQA2* and *FCER1A*) showed the dysregulation of DC function in COVID-19 (Fig. 6A). In lung, *CD40*, *CD80*, *CD83* and *HLA-DQA2* were upregulated while *CD86* and *FCER1A* were decreased in mild COVID-19 as compared to healthy controls. Similar patterns were observed on *CD40*, *CD86* and *HLA-DQA2* in both blood datasets while inconsistent results of *CD83* and *FCER1A* were observed in Lee and Wilk PBMC datasets. Compare to mild cases, severe COVID-19 showed upregulated *CD40* as well as downregulated *CD83*, *HLA-DQA2* and *FCER1A* in all three tissues. Interestingly, asymptomatic cases showed similar expression of those markers with healthy controls in blood.

In addition, we investigated the expression of MHC class II molecules (MHCII) and Fc receptors (FcRs) and found that they were broadly activated in APCs in lungs of mild COVID-19 patients, with a MHCII subset (*HLA-DRA*, *HLA-DMB*, *HLA-DRB1*, *HLA-DPB1*, *HLA-DQB1*, *HLA-DMA*) were downregulated (Fig. 6B). Compared to mild cases, severe cases showed decreased

MHCII expression in airway APCs but not significantly in blood. The result was in agreement with above pathway analysis that antigen processing and presentation were activated in mild cases but inhibited specifically in lungs of severe cases. Significantly in lung and blood APCs, HLA-DQA2 expression were increased in mild cases as compared to healthy controls but downregulated in severe cases as compared to mild cases. Interestingly, compared to healthy controls, the global change of MHCII and FcRs gene expression in blood were associated with COVID-19 severity, with upregulation in asymptomatic cases, no significant change in mild cases and downregulation in severe cases (Fig. S9).

Together, these observations indicate the ability of DCs for T-cell stimulation is induced but the maturation of DCs is inhibited in both lung and blood of severe COVID-19, and specifically the antigen presentation ability of APCs is reduced in lung, which is the primary site of infection.

Conventional DC subsets were depleted and new immature DC subsets were accumulated in severe COVID-19

We further investigated the variation of DC subsets in nasopharynx/pharynx, BALF and PBMC samples from COVID-19 patients and healthy controls. Based on known markers (Fig. S10), four DC subsets were identified in the nasopharynx/pharynx samples, including type I and II conventional dendritic cells (cDC1 and cDC2), Mø-like DC which expressed Mø markers S100A8 and S100A9, Plasmacytoid dendritic cell (pDC) and a new subset of CD22⁺ITM2C⁺ DC; seven subsets were identified in the BALF samples, including cDC1, cDC2, mature cDC2, Mø-like DC, pDC and new subsets CD22⁺ DC and ANXA1⁺ DC; four subsets were identified in the PBMC samples from the Lee dataset, including cDC1, cDC2, mature cDC2 and Mø-like DC; four subsets were identified in the PBMC samples from the Wilk dataset, including cDC1, cDC2, mature cDC2 and Mø-like DC (Fig. 7A). The integration of all datasets found that these subsets were conservative among tissues (Fig. S11). CD22⁺ITM2C⁺ DC in nasopharynx/pharynx samples were clustered together with CD22⁺ DC in BALF samples, which were characterized by

the activated immune response ($q = 1.17 \times 10^{-5}$) and interferon gamma response ($q = 1.17 \times 10^{-5}$).

Among DCs, the proportion of cDC2 was severity-dependently decreased in both lung and blood of COVID-19 (Fig. 7B). Inversely, the mature cDC2 was increasingly correlated with disease severity in lung BALF samples. Such increase was also found in PBMC with mild COVID-19 but not in severe cases which might be due to its limited cell detection of DC cells (N=12). pDC showed a notable augmentation in BALF and depletion in PBMC in mild cases but not in severe cases, which may reflect the different migration activeness of pDC from blood to lung in mild and severe COVID-19. Interestingly, all tissues in severe cases showed augmentation of immature DC subsets with decreased mature markers *CD83*, T-cell stimulation activators (*CD40*, *CD80*, *CD86*) and HLA genes, including $CD22^+ITM2C^+$ DC and Mø-like DC in nasopharynx/pharynx samples, $ANXA1^+$ DC and pDC in BALF samples, Mø-like DC and pDC in PBMC samples. Indeed, in nasopharynx/pharynx samples, the proportion of $CD22^+ITM2C^+$ DC was significantly positively correlated with that of M0 Mø ($P = 8.6 \times 10^{-5}$), resting CD4 memory T cells ($P = 0.028$) and resting mast cells ($P = 0.024$) (Fig. S12). In addition, we found the BALF specific $ANXA1^+$ DC subset showed high expression of COX related genes *PTGS1*, *PTGS2*, *HPGDS*, *ALOX5* and *LTC4S*, which may be responsible for the DC immunity suppression²⁴, together with *ANXA1*²⁵.

We observed a clear shift from conventional DCs to pDC on single cell trajectory in COVID-19 BALF and PBMC, in response to viral infection (Fig. 7C). However, the shift was trapped in the path in severe cases, producing immature subsets. The blockade was also observed in nasopharynx/pharynx with severe COVID-19 (Fig. S13). Further we found that both bursting frequency and size of MCHII genes were inhibited in the lung specific immature subset $ANXA1^+$ DC as compared to cDC2 and pDC (Fig. S14). Increased frequency and size of Cox genes were also observed. This indicate the SARS-CoV-2 infection may inhibit the DC maturation by

regulating the expression kinetics parameters (bursting frequency and bursting size) of related genes.

Discussion

ACE2, DC-SIGN and L-SIGN are three receptors of both SARS-CoV and SARS-CoV-2. No data is available to indicate they are dependent viral entry portals and we did not find significant correlations of the gene expression between ACE2 and that of DC-SIGN and L-SIGN (Fig. S15). Given that DC-SIGN is mainly expressed on the surface of DCs and Mø, the viral infection to immune cells may directly link to the immunopathogenesis and disease severity of COVID-19. Indeed, we found higher gene expression of *ACE2* and *CD209* in upper airway cells of COVID-19 ARIs compared to non-viral ARIs, and *CD209* plasma protein expression was correlated COVID-19 risk and severity. We also observed their association with the variation of immune cell activation in upper airway cells of COVID-19 ARIs that high expression was only found in the T/Mø activated cells. This might be a result from the immune stimulation by intensive viral attack to ACE2 and DC-SIGN expressing cells. This may also reflect the negative correlation of *CD209* expression with neutrophil percentage and the positive correlation with T cell percentage, which were detected by our large-scale population genetic association study. Indeed, the activated neutrophils produce TNF-alpha and induce DC maturation which lower the *CD209* expression²⁶; *CD209* mediates the activation of T cells²⁷. The neutrophil-to-lymphocyte ratio has been studied as a severity marker in COVID-19²⁸ and as a valid prognostic factor in various solid tumors and other chronic diseases²⁹. Therefore, the interaction of *CD209* and DCs with neutrophils and T cells may play an important role in mediating cytokine storm coupled with limited anti-viral capability, which are keys in COVID-19 pathogenesis³⁰. Further investigation is required to elucidate this interaction and the causal effect of *ACE2* or *CD209* to the COVID-19 risk.

For the first time, we performed a systematic investigation of the expression of SARS-CoV-2 receptors in single cells of upper airway, lower airway and blood of COVID-19 patients. We found *CD209* expression and the percentage of DCs and MoD Mø or monocytes were associated with COVID-19 severity. Interestingly, the associations were site specific. In the lung and upper airway with mild infection, DCs were induced for an active immune response and an cell augmentation. In the cases of severe infection, the decrease of DCs proportion and maturation could be a sign exhaustion of DCs. Also, the decreased expression of *CD209* in DCs of COVID-19 lungs may be a result of cell death caused by direct viral infection. Differently, blood showed induced DC activation and increased *CD209* expression, which may indicate that DCs are stimulated in blood but not attacked by virus. Indeed, no SARS-CoV-2 sequencing reads were detected from COVID-19 PMBC¹⁶. Interestingly, DCs in lungs of severe COVID-19 showed upregulation of T cell stimulation but downregulation of antigen presentation and maturation, indicating that DCs may stimulate innate immune system but fail to recognize SARS-CoV-2. This may lead to the negatively correlated cytotoxic follicular helper response with antibody levels to SARS-CoV-2 spike protein in hospitalized COVID-19 patients³¹. SARS-CoV-2 might use an escape mechanism similar to HIV-1 which hides in DCs and uses DC-SIGN as a trans-receptor for efficient transmission to T cells, and also similar to *Mycobacteria tuberculosis* (*M. tb*) which subverts DCs by targeting DC-SIGN and inhibiting maturation³². The stimulated and “blinded” immune systems could be responsible for the cytokine storm as well as severe ARDS suffering COVID-19 critical cases. MHCII genes especially HLA-DQA2 might be involved in this pathogenesis, which were found to be decreased in lung of severe cases compared to mild cases. This may also link to the olfactory impairment which is often seen in patients with COVID-19, given that MHC are essential in individual olfactory perception³³.

The observed broad downregulation of MHCII genes in APCs was aligned with recent findings that dysfunctional monocytes^{34,35} and B cells³⁶ in severe COVID-19. Here, we report a shift from cDCs to pDCs in COVID-19 cases, which leads to the marked disease severity-

dependent depletion of cDC2 in all studied tissues. Strikingly, the shift was blocked in immature subsets including CD22⁺ DC and ANXA1⁺ DC with suppressed activation markers. This immunosuppression of DCs may contribute to the variation of disease severity through the interactions between DCs and T cells and other immune cells. Indeed, we found the immature subtype CD22⁺ITM2C⁺ DC was significantly positively correlated with the resting subsets of Mø, CD4mT and mast cells in upper airway.

In this study, we also investigated the smoking effect on respiratory gene expression of these three receptors of both SARS-CoV and SARS-CoV-2. We found ever-smokers had significantly higher *ACE2* and *CD209* gene expression than non-smokers, respectively in lung AT1 cells and monocytes/DCs. Our results indicate that this smoking effect might be mediated by methylation regulation. Indeed, methylation switch *CD209* genes during the differentiation of human Monocytes to dendritic cells³⁷. Also, DCs maturation and signaling pathways such as TLR signaling for viral detection and innate immune initiation were inhibited by smoking. Thus, smoking may accomplice the escape of SARS-CoV-2 from immune surveillance by targeting DCs, as shown in this study that antigen presentation and maturation are inhibited in DCs in severe COVID-19 lungs. Indeed, cigarette smoking has been confirmed to increase the susceptibility to various respiratory diseases such as pneumococcal disease and pneumonia^{38,39}. Severance et al. also identified smoking status as a risk factor for the exposure of four non-SARS coronavirus strains among US population⁴⁰. Interestingly, we also found smoking induces the DC proportion and enhances immune responses related pathways in DCs. These results indicate that DCs from smoking individuals have lower ability to stimulate T cells to attack a pathogen but actively induce immune responses and release cytokines, which may partially contribute to the cytokine storm in severe COVID-19 patients. Together with the upregulation of *ACE2* and *CD209* expression by smoking, this may explain the clinical presentation of 1,099 cases of COVID-19 that the smokers had a higher risk of severe disease⁴¹.

Collectively, this study provides important pieces of puzzle of COVID-19 about dysfunctional DC cells from the expression of receptors of SARS coronavirus, the effect and potential risk of smoking, and remodeling of DC activation and redistribution of DC subsets. Although further studies with a larger sample size of single cell or single cell type studies will be needed to properly assess this matter, this study provide important hints for vaccine development, as well as the variation of COVID-19 severity and pathogenesis.

STAR★Methods

Key Resources Table

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Deposited Data		
TCGA bulk RNA-seq transcriptome data of normal lung tissues from patients with lung cancer adenocarcinoma	Firehose https://gdac.broadinstitute.org/	Level 3, version 2016_07_15
GSE40419 bulk RNA-seq transcriptome data of normal lung tissues from patients with lung cancer adenocarcinoma	GEO	GSE40419
GSE10072 bulk microarray transcriptome data of normal lung tissues from patients with lung cancer adenocarcinoma	GEO	GSE10072
GSE63127 bulk microarray transcriptome datasets of healthy small airway epithelium	GEO	GSE63127
GSE19667 bulk microarray transcriptome datasets of healthy small airway epithelium	GEO	GSE19667
GSE5058 bulk microarray transcriptome datasets of healthy small airway epithelium	GEO	GSE5058
GSE7895 bulk microarray transcriptome datasets of healthy large airway epithelium	GEO	GSE7895
mNGS data of nasopharynx/pharynx samples from ARIs <i>with or without COVID-19</i>	⁴²	https://github.com/czbiohub/COVID-19-transcriptomics-pathogenesis-diagnostics-results
GSE131391 scRNA-seq data of bronchial epithelial cells from ever-smokers and non-smokers	GEO	GSE131391

GSE122960 scRNA-seq data of normal lung tissues from ever-smokers and non-smokers	GEO	GSE122960
Madisson scRNA-seq data of normal lung tissues from ever-smokers and non-smokers	NCBI BIOPROJECT	PRJEB31843
scRNA-seq datasets of nasopharynx/pharynx samples from COVID-19 patients and healthy controls	⁴³	https://doi.org/10.6084/m9.figshare.12436517
scRNA-seq datasets of BALF samples from COVID-19 patients and healthy controls	GEO	GSE145926
scRNA-seq datasets of Lee PBMC samples from COVID-19 patients and healthy controls	GEO	GSE149689
scRNA-seq datasets of Wilk PBMC samples from COVID-19 patients and healthy controls	⁴⁴	https://www.COVID-19cellatlas.org/#wilk20
TCGA bulk methylation data of normal lung tissues from patients with lung cancer adenocarcinoma	TCGA	v25
GSE32861 bulk methylation data of normal BALF samples	GEO	GSE32861
GSE133062 bulk methylation data of normal BALF s	GEO	GSE133062
GSE92511 bulk methylation data of normal lung samples	GEO	GSE92511
GSE139032 bulk methylation data of normal lung samples	GEO	GSE139032
GSE32863 bulk microarray transcriptome data of normal lung samples	GEO	GSE32863
Plasma protein QTL summary statistics	⁴⁵	http://www.phpc.cam.ac.uk/ceu/proteins/
COVID-19 risk GWAS summary statistics	NIH GRASP	files with name "ALLwhites" at 06-05-2020) for COVID-19 risk
COVID-19 severity GWAS summary statistics	NIH GRASP	study of Ellinghaus et al. ⁴⁶
Processed scRNA-seq data of DCs	This paper	https://thecailab.com/SCANNER
Supplemental Table S1, Table S2, Table S3, Table S4	This paper	https://data.mendeley.com/datasets/bjzfxw4jrf/1
Software and Algorithms		
R	https://www.cran.r-project.org	v4.0.2
RMA	Bioconductor	affy v3.11
edgeR	Bioconductor	v3.30.3
CIBERSORT	⁴⁷	https://cibersort.stanford.edu/

MuSiC	GitHub	https://github.com/xuranw/MuSiC
STAR	GitHub	v2.7 https://github.com/alexdobin/STAR
FastQC	http://www.bioinformatics.babraham.ac.uk/projects/fastqc	v0.11.9
Qualimap	http://qualimap.conesalab.org/	V2.2.1
MultiQC	GitHub	https://github.com/ewels/MultiQC
bcbioRNAseq	Bioconductor	v0.2.9
limma-voom	Bioconductor	v3.44.3
Seurat	GitHub	v3.0 https://github.com/satijalab/seurat
Monocle	Bioconductor	v2.16.0
GSEAPreranked	GenePattern, https://www.genepattern.org/#	v1
Cytoscape	https://cytoscape.org/	v3.8.1
StringAPP	http://apps.cytoscape.org/apps/stringapp	v1.6.0
PhenoScanner	http://www.phenoscanner.medschl.cam.ac.uk/	v2
PhenomeXcan	http://apps.hakymilab.org/phenomexcan/	February 28, 2020
TwoSampleMR	GitHub	https://github.com/MRCIEU/TwoSampleMR
Rstan	CRAN	v2.21.2
SCANNER	⁴⁸	https://thecailab.com/SCANNER

Bulk transcriptomics

Normal lung and airway samples from ever-smokers and non-smokers

We used eight datasets (N = 1162) to investigate the gene expression of three SARS coronavirus receptors (ACE2, DC-SIGN and L-SIGN, with gene symbols *ACE2*, *CD209* and *CLEC4M*) in bulk tissues, including four datasets of normal lung tissues from patients with lung cancer adenocarcinoma (TCGA RNA-seq dataset (N = 48)⁴⁹, Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ) microarray dataset⁵⁰ (N = 475), Gene Expression

Omnibus (GEO) GSE40419 RNA-seq dataset⁵¹ (N = 74) and GSE10072 microarray dataset⁵² (N = 33)), three microarray datasets of healthy small airway epithelium (SAE) samples (GSE63127⁵³ (N = 230), GSE19667⁵⁴ (N = 116) and GSE5058⁵⁵ (N = 24)) and a microarray dataset of healthy large airway epithelium (LAE) samples from GSE7895⁵⁶ (N = 104). We studied the Reads Per Kilobase per Million mapped reads (RPKM) values for RNA-seq data and Robust Multi-array Average (RMA)⁵⁷ values for microarray data. All data were log2 transformed to improve normality. Never-smokers and ever-smokers (including current and former smokers) were identified in each original study based on self-reported smoking history. Multivariate linear regressions were used to test the association of *ACE2*, *CD209* and *CLEC4M* gene expression with smoking status adjusted for age and sex. Meta-analysis was performed by pooling effect size and standard error estimated from each study using a random effects model with Hunter-Schmidt estimator.

Upper airway samples from patients with or without COVID-19

We studied the metagenomic next generation sequencing (mNGS) data of nasopharynx/pharynx samples from 197 patients with acute respiratory illnesses, including 94 patients confirmed with SARS-CoV-2 infection by clinical PCR and 103 with no virus detected⁴². The host gene expression read counts and the CPM (read counts for million) of SARS-CoV-2 virus were analyzed. We normalized the read counts of *ACE2* and *CD209* using the TMM method and calculated CPM using edgeR⁵⁸. The data for *CLEC4M* was not available.

We deconvoluted the immune cell composition from these bulk RNA-seq data using CIBERSORT⁴⁷ with its signature matrix, LM22. In each sample, the proportions of 22 human hematopoietic cell types were inferred, including naïve and memory B cells, plasma cells, 7 T cell types (CD8, CD4 native, memory resting CD4, memory activated CD4, follicular helper, regulatory (Tregs) and gamma delta), NK cells (resting and activated), monocytes, macrophages (M0, M1 and M2), dendritic cells (resting and activated), mast cells (resting and

activated), eosinophils and neutrophils. Using transcriptome profiles of DC subsets identified in below scRNA-seq datasets of nasopharynx/pharynx samples, we also estimated the composition of DC subsets in these bulk RNA-seq data using MuSiC⁵⁹.

Linear regression was used to test the difference of gene expression or immune cell proportions between sample groups as well as their association with SARS-CoV-2 viral load in samples.

Blood samples from ARDS cases and controls

From the Molecular Epidemiology of ARDS (MEARDS) prospective cohort study⁶⁰, 160 Acute Respiratory Distress Syndrome (ARDS) cases and 142 controls were recruited for RNA-Seq analysis of blood samples. RNA was extracted by PAXgene Blood RNA Kit (QIAGEN) and selected by using oligo(dT) beads. Sequencing libraries were built using MGIEasy RNA Library Prep Kit and subsequently sequenced on the MGISEQ-2000 platform. The 100 bp pair-end sequencing reads were filtered to remove low-quality, adaptor-polluted and high content of unknown base (N) reads. Further, sequencing reads were mapped to reference genome GRCh38 using STAR⁶¹ and counts of reads aligning to known genes were generated by featureCounts⁶². Quality controls were performed for evenness of coverage, rRNA content, genomic context of alignments using FastQC

(<http://www.bioinformatics.babraham.ac.uk/projects/fastqc>), Qualimap⁶³, MultiQC

(<https://github.com/ewels/MultiQC>), and bcbioRNAseq (version 0.2.9)⁶⁴. Then, limma-voom⁶⁵ was used to perform whole-transcriptome differential expression analysis from raw counts.

Single-cell transcriptomics

Normal airway samples from ever-smokers and non-smokers

We analyzed three single-cell RNA sequencing datasets including GSE131391⁶⁶, GSE122960⁶⁷ and a dataset from Madisson *et al.*⁶⁸. The GSE131391 dataset focused on bronchial epithelial

cells, ALCAM+ epithelial cells and CD45+ white blood cells from 6 never- and 6 current-smokers. The GSE122960 dataset was from lung tissues of 8 lung transplant donors, including 5 never- and 3 ever-smokers. The Madisson dataset was from lung tissues of 4 never- and 3 ever-smokers. Sequencing read counts in single cells were downloaded, and subsequent data analyses were performed using the Seurat 3.0 package⁶⁹, including data normalization, high variable feature selection, data scaling, dimension reduction and cluster identification. The Louvain method was used on the top 20 principle components to identify clusters, which were visualized in reduced dimensions of Uniform Manifold Approximation and Projection (UMAP). Cell types were assigned to clusters based on markers used in each original study. In GSE131391 samples, we identified club cells, goblet cells, ciliated cells, CD45+ white blood cells (WBC), ionocytes, basal cells and a basal cell sub-population (basal-2) which was shown in smokers. In GSE122960 samples, we identified alveolar type I cells (AT1), alveolar type II cells (AT2), macrophages, monocytes, endothelial cells, ciliated cells, club cells, B cells, T/NKT cells, DCs and fibroblast cells. In samples from the study of Madisson et al., we identified AT1, AT2, macrophages, monocytes, ciliated cells, B cells, T cells, NKT cells, DCs, mast cells, fibroblast cells, muscle cells, plasma cells, blood vessel endothelial cells (VesselEpi-b) and lymph vessel endothelial cells (VesselEpi-l).

Upper airway, lower airway and peripheral blood samples from COVID-19 patients and healthy controls

We investigated the gene expression of *ACE2*, *CD209* and *CLEC4M* in scRNA-seq datasets of nasopharynx/pharynx, BALF and PBMC samples from COVID-19 patients and healthy controls. The nasopharynx/pharynx data were available in the study of Chua et al.⁴³ with the count matrix and cell type identification derived from 11 moderate and 8 critical COVID-19 patients and 5 healthy controls. We also downloaded the count data of BALF samples from 6 severe and 3 mild COVID-19 patients as well as 3 healthy controls from GEO GSE145926¹⁵. Also, the count

data from PBMC samples of 6 severe, 4 mild, and 1 asymptomatic COVID-19 patients and 4 healthy controls were downloaded from GEO GSE149689 of Lee et al.⁷⁰. In addition, we analyzed another PBMC scRNA-seq dataset from the study of Wilk et al.⁴⁴, which was from 6 healthy controls and 7 COVID-19 patients. 4 of 8 COVID-19 samples were collected from patients who were diagnosed with ARDS and were ventilated. Two samples were collected from one patient in the non-severe condition without ventilation and in the severe condition with ventilation.

scRNA-seq data processing was performed using Seurat with steps same as above. 110145 cells including 9326 DCs were analyzed in the nasopharynx/pharynx dataset. 71415 cells including 1484 DCs were analyzed in the BALF dataset. 58187 cells including 526 DCs were analyzed in the Lee et al. PBMC dataset. 36925 cells including 514 DCs were analyzed in the Wilk PBMC dataset. Cell types in the nasopharynx/pharynx dataset and the Wilk et al. PBMC dataset were identified by their original studies. Following the approaches used in the study of Wilk et al.⁴⁴, we used SingleR⁷¹ and markers used in each original study, we identified cell types for cell clusters detected in the BALF and Lee et al. PBMC datasets. In the nasopharynx/pharynx samples, we identified squamous cells, non-resident macrophages (NR macrophages), monocyte-derived macrophages (MoD macrophages), resident macrophages (R macrophages), neutrophils, CD4⁺ T cells, CD8⁺ T cells, B cells, ciliated cells, NK cells, NKT cells, Diff ciliated, DCs, IFNG-responsive cells (IRC), basal, secretory, differentiating secretory (Diff secretory), outliers epithelial cells (Out epithelial), ionocytes, Unknown epithelial cells, mast cells and FOXN4⁺ cells. In the BALF samples, we identified CD8⁺ T cells, CD4⁺ memory T cells (CD4m T), gamma delta T cells (gd T), alveolar macrophages (A macrophages), MoD macrophages, epithelial cells, DCs, NK cells, plasma B cells (PB), neutrophils and monocytes. In the Lee PBMC dataset, we identified immature B cells, naive B cells, CD4m T cells, CD8⁺ T cells, CD4⁺ T cells, erythroblasts, gd T cells, CD16⁺ monocytes, CD16⁻ monocytes, platelets, NK cells, DCs and intermediate monocytes (Int monocytes). In the Wilk PBMC dataset, we

identified activated granulocytes (Act granulocytes), B cells, CD14⁺ monocytes, CD16⁺ monocytes, CD4⁺ T cells, CD4m T cells, naive CD4⁺ T cells (CD4n T), effector CD8⁺ T cells (CD8eff T), CD8m T cells, class-switched B cells (Switched B), DCs, gd T cells, IgA-producing PB cells (IgA PB), IgG-producing PB cells (IgG PB), neutrophils, NK cells, DCs, platelets, red blood cells (RBC), as well as stem cells and eosinophils (SC & Eosinophil). To compare gene expression in groups, Wilcoxon rank sum test was used.

To identify DC subsets, we used well evidenced markers for cDC1 (*CLEC9A*, *C1orf54*, *HLA-DPA1*, *CADM1*, *CAMK2D*, *XCR1*), cDC2 (*CD1C*, *FCER1A*, *CLEC10A*), pDC (*DAB2*, *GZMB*, *JCHAIN*, *SERPINF1*, *ITM2C*, *CLEC4C*, *LILRA4*), mature DC (*LAMP3*, *CD86*, *CD83*, *CD40*, *ICAM1*, *ITGA4*, *CCL8*, *CCL22*, *CCL17*, *CXCL8*, *CXCL9*, *CXCL10*, *CXCL11*, *CCR7*), macrophage-like DC (*S100A9*, *S100A9*, *S100A8*, *VCAN*, *LYZ*, *CD14*), AXL⁺ DC (*ANXA1*, *AXL*, *PPP1R14A*, *SIGLEC6*, *CD22*) and non-classical DC (*FCGR3A*, *CX3CR1*). To evaluate the similarity of DC subtypes identified in above scRNA-seq datasets, we integrated these datasets using Seurat and visualized the integrated matrix with UMAP. Monocle⁷² was used to infer the single cell trajectory.

Methylation analysis of *CD209* and *ACE2*

In this study, five datasets (N = 237) of normal lung tissues were used to investigate the association of smoking and DNA methylation of *CD209*, including two datasets of normal lung tissues from patients of lung adenocarcinoma from TCGA⁴⁹ (Illumina 450K BeadChip, N = 55) and GSE32861⁷³ (Illumina 27K BeadChip, N = 59), one dataset of BALF cells from GSE133062⁷⁴ (Illumina MethylationEPIC BeadChip, N = 35), and two datasets of normal non-malignant lung samples from GSE92511⁷⁵ (Illumina 450K BeadChip, N = 16) and GSE139032⁷⁶ (Illumina 27K BeadChip, N = 77). Smoking history was determined by self-reported history. Multivariate linear regressions were used to test the association of the M-values of *CD209* methylation probes with smoking status adjusted for sex and age. Using the effect size and

standard error estimates from each study, a random-effects meta-analysis was performed as described before. With paired data from the GSE32863⁷³ mRNA expression and the GSE32861 methylation measurements, we also evaluated the correlation of CD209 expression abundance and methylation level in 58 paired samples.

Group comparison and association testing

Linear regression was used to evaluate the association between variables and perform two-group comparison. To evaluate the association of *CD209* expression with tumor stage and survival of lung adenocarcinoma tumors, ordinal regression and Cox proportional hazard model were used respectively.

Pathway and network analyses

Pathway and network analyses were performed to systematically investigate biological processes involved in smoking or COVID-19. We calculated transcriptome-wide fold changes (FC) of expression and ranked the differential expression according to $\log_2\text{FC}$. For Based on these ranks, preranked Gene Set Enrichment Analysis (GSEA)⁷⁷ was applied to evaluate the enrichment of Kyoto Encyclopedia of Genes and Genomes (KEGG)⁷⁸ pathways. Further, the summary statistics of GSEA analysis were used to build connection networks of detected pathways by the Enrichment Map implemented in Cytoscape⁷⁹. Pathways with $Q\text{-value} < 0.2$ were included into networks and the connectivity strength was determined by an edge cutoff as 0.25. In addition, networks of genes with absolute value of the average of $\log_2\text{FC} > 1$ were constructed using the Cytoscape StringAPP⁸⁰.

Inference and comparison of transcriptional bursting kinetics between DC subsets

To infer the bursting kinetics from single cell transcriptomic data, we developed a Bayesian hierarchical framework to estimate the bursting kinetic parameters (i.e. transcribe rate s ,

activation rate k_{on} and deactivation rate k_{off}). In the spirit of the conventional Poisson-Beta model (Vu et al., 2016), our method considered the transcriptional bursting process characterized by burst size s/k_{off} and burst frequency k_{on} . A major limitation of Poisson-Beta model is that it neglects the remarkable noisy nature of sequencing technology⁸¹⁻⁸³, which usually leads to overestimation of the dispersion and consequently jeopardize the validity to infer bursting kinetics. To address this issue, we reconstructed the mean-variance relationship by utilizing the Generalized additive model (GAM) that can resist and down-weight the effect of a small number of atypically high dispersion estimates especially for genes with few counts. The re-estimated dispersion BCV based on the re-fitted mean-variance function was then incorporated into the framework, assuming that the sampling distribution of the underlying mean λ is gamma. Specifically, let $y \sim Poisson(\lambda)$ denotes the observed number of mRNA molecules,

$$\lambda \sim gamma(1/BCV'^2, spBCV'^2)$$

$$p|k_{on}, k_{off} \sim Beta(k_{on}, k_{off})$$

Where p denotes the fraction of time that a gene spends in the active state. With the proper choices of the priors and hyperpriors, the posterior parameters were estimated via Markov Chain Monte Carlo (MCMC) algorithm implemented in Rstan⁸⁴.

We also formulated a differential bursting analysis framework that can further explored the change in bursting kinetics between different study conditions. After applying the MCMC method, the MCMC samples provided various representative combinations of bursting frequency and size values, while the credible differences of bursting frequency and size could be examined by computing and summarizing the changes at each combination of parameters values. Those credible differences could then be used to assess the credibility of “null value”⁸⁵.

We applied the proposed method to investigate the differences of bursting kinetics in ANXA1⁺ DCs in COVID-19 lung compared to pDCs and cDC2s separately. With the processed scRNA-

seq count data generated from previous pipeline, changes in bursting frequency and size estimates (in $\log_2$ scale) were computed.

Transcriptome-based phenome-wide association study

We utilized public resources to search for CD209 related traits/disease candidate.

PhenoScanner⁸⁶ was used to obtain associated phenotypes from genome-wide association study (GWAS) studies. Also, PhenomeXcan⁸⁷ underlying phenome-wide association study (PheWAS) analytic framework was used to infer associations of CD209 lung expression and multiple traits, by integrating GWAS summary statistics of 4,091 traits and Genotype-Tissue Expression data from GTEx⁸⁸ lung tissue version 8.

Mendelian Randomization analysis

Mendelian Randomization (MR) analysis provides evidence for a causal relationship between exposure and outcome. To infer the causal effect of plasma expression of ACE2 and DC-SIGN on COVID-19 risk and severity, we applied the TwoSampleMR R package⁸⁹ for MR analysis.

For exposures of protein expression of SARS-CoV-2 receptors, we obtained publicly available plasma protein QTL summary statistics from the study of Sun *et al.*⁴⁵. For outcomes of COVID-19 risk and severity, we separately required GWAS summary statistics from GRASP

(<https://grasp.nhlbi.nih.gov/COVID-19GWASResults.aspx>; files with name “ALLwhites” at 06-05-2020) for COVID-19 risk, and that from the study of Ellinghaus *et al.*⁴⁶ for COVID-19 severity.

Independent genetic instruments of exposures were selected for MR analysis based on strict criteria of minor allele frequency (MAF) > 0.05, linkage disequilibrium (LD) $r^2 < 0.01$ within a clumping window of 10,000 kb, and beyond genome-wide significance ($P < 5 \times 10^{-8}$). As there were no genetic instruments of plasma ACE2, the significance threshold for selecting instruments was set as $P < 10^{-4}$. Ultimately, we found 3, 60, and 1 SNPs as independent genetic instruments for plasma CD209, ACE2, and CLEC4M, respectively. Inverse-variance-weighted

(IVW), weighted median, and MR-Egger regression methods were used to calculate effect size (β) and corresponding standard error (SE). The Wald ratio method was used if only one genetic instrument remained. Heterogeneity was estimated using MR-Egger and IVW methods. Directional pleiotropy was estimated via MR-Egger intercept test.

Software

All data management, statistical analyses and visualizations were accomplished using R software version 4.0.2.

Data availability

The data derived from MEARDS was accessible upon request to Dr. David C. Christiani (dchris@hsph.harvard.edu). Data from other studies were openly available to the public without registration or application for access. Processed single cell transcriptomics data were available for visualization and exploration in SCANNER⁴⁸ (<https://www.thecailab.com/scanner/>). The hosted data include three datasets from the normal airway samples from ever-smokers and non-smokers, as well as four datasets from the DCs of nasopharynx/pharynx, BULF and PBMC samples from COVID-19 patients and healthy people.

Ethical oversight

All the data were de-identified and study approval has been stated in original studies. The MEARDS study was reviewed and approved by institutional review boards of Massachusetts General Hospital (MGH) and Harvard School of Public Health (project approval number: 1999P0086071/MGH).

Reference

1. Chan JF-W, Yuan S, Kok K-H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet* 2020:S0140-6736(20)30154-9.
2. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. *Methods Mol Biol* 2015;1282:1-23.
3. Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 2020:10.1038/s41586-020-2012-7.
4. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. *J Virol* 2020:JVI.00127-20.
5. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020:S0140-6736(20)30183-5.
6. Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature* 2003;426:450-4.
7. Yang Z-Y, Huang Y, Ganesh L, et al. pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. *J Virol* 2004;78:5642-50.
8. Jeffers SA, Tusell SM, Gillim-Ross L, et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. *Proc Natl Acad Sci U S A* 2004;101:15748-53.
9. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 2020;579:270-3.
10. Amraie R, Napoleon MA, Yin W, et al. CD209L/L-SIGN and CD209/DC-SIGN act as receptors for SARS-CoV-2 and are differentially expressed in lung and kidney epithelial and endothelial cells. *bioRxiv* 2020.
11. Gardner JP, Durso RJ, Arrigale RR, et al. L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. *Proc Natl Acad Sci U S A* 2003;100:4498-503.
12. Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. *Nat Rev Immunol* 2020;20:363-74.
13. Khoo U-S, Chan KYK, Chan VSF, Lin CLS. DC-SIGN and L-SIGN: the SIGNS for infection. *J Mol Med (Berl)* 2008;86:861-74.
14. da Silva RC, Segat L, Crovella S. Role of DC-SIGN and L-SIGN receptors in HIV-1 vertical transmission. *Hum Immunol* 2011;72:305-11.
15. Liao M, Liu Y, Yuan J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. *Nat Med* 2020;26:842-4.
16. Wilk AJ, Rustagi A, Zhao NQ, et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. *Nat Med* 2020;26:1070-6.
17. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020.
18. Cai G, Bosse Y, Xiao F, Kheradmand F, Amos CI. Tobacco Smoking Increases the Lung Gene Expression of ACE2, the Receptor of SARS-CoV-2. *Am J Respir Crit Care Med* 2020;201:1557-9.
19. Ellul MA, Benjamin L, Singh B, et al. Neurological associations of COVID-19. *Lancet Neurol* 2020;19:767-83.
20. Montalvan V, Lee J, Bueso T, De Toledo J, Rivas K. Neurological manifestations of COVID-19 and other coronavirus infections: A systematic review. *Clin Neurol Neurosurg* 2020;194:105921.
21. Hatterer E, Touret M, Belin MF, Honnorat J, Nataf S. Cerebrospinal fluid dendritic cells infiltrate the brain parenchyma and target the cervical lymph nodes under neuroinflammatory conditions. *PLoS One* 2008;3:e3321.
22. Costello F, Dalakas MC. Cranial neuropathies and COVID-19: Neurotropism and autoimmunity. *Neurology* 2020;95:195-6.
23. Ziegler CGK, Allon SJ, Nyquist SK, et al. SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. *Cell* 2020;181:1016-35 e19.
24. Sharma S, Stolina M, Yang SC, et al. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. *Clin Cancer Res* 2003;9:961-8.
25. Huggins A, Paschalidis N, Flower RJ, Perretti M, D'Acquisto F. Annexin-1-deficient dendritic cells acquire a mature phenotype during differentiation. *FASEB J* 2009;23:985-96.
26. van Gisbergen KP, Sanchez-Hernandez M, Geijtenbeek TB, van Kooyk Y. Neutrophils mediate immune modulation of dendritic cells through glycosylation-dependent interactions between Mac-1 and DC-SIGN. *J Exp Med* 2005;201:1281-92.
27. Engering A, Geijtenbeek TB, van Vliet SJ, et al. The dendritic cell-specific adhesion receptor DC-SIGN internalizes

antigen for presentation to T cells. *J Immunol* 2002;168:2118-26.

28. Liu J, Liu Y, Xiang P, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. *J Transl Med* 2020;18:206.

29. Templeton AJ, McNamara MG, Seruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. *J Natl Cancer Inst* 2014;106:dju124.

30. Kuppalli K, Rasmussen AL. A glimpse into the eye of the COVID-19 cytokine storm. *EBioMedicine* 2020;55:102789.

31. Meckiff BJ, Ramírez-Suástegui C, Fajardo V, et al. Imbalance of regulatory and cytotoxic SARS-CoV-2-reactive CD4 T cells in COVID-19. *Cell* 2020.

32. van Kooyk Y, Geijtenbeek TB. DC-SIGN: escape mechanism for pathogens. *Nat Rev Immunol* 2003;3:697-709.

33. Milinski M, Croy I, Hummel T, Boehm T. Major histocompatibility complex peptide ligands as olfactory cues in human body odour assessment. *Proc Biol Sci* 2013;280:20122889.

34. Schulte-Schrepping J, Reusch N, Paclik D, et al. Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment. *Cell* 2020;182:1419-40 e23.

35. Silvin A, Chapuis N, Dunsmore G, et al. Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. *Cell* 2020;182:1401-18 e18.

36. Kaneko N, Kuo HH, Boucay J, et al. The Loss of Bcl-6 Expressing T Follicular Helper Cells and the Absence of Germinal Centers in COVID-19. *SSRN* 2020:3652322.

37. Bullwinkel J, Ludemann A, Debarry J, Singh PB. Epigenotype switching at the CD14 and CD209 genes during differentiation of human monocytes to dendritic cells. *Epigenetics* 2011;6:45-51.

38. Huttunen R, Heikkinen T, Syrjänen J. Smoking and the outcome of infection. *J Intern Med* 2011;269:258-69.

39. Nuorti JP, Butler JC, Farley MM, et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. *N Engl J Med* 2000;342:681-9.

40. Severance EG, Bossis I, Dickerson FB, et al. Development of a nucleocapsid-based human coronavirus immunoassay and estimates of individuals exposed to coronavirus in a U.S. metropolitan population. *Clin Vaccine Immunol* 2008;15:1805-10.

41. Guan W-j, Ni Z-y, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China. *medRxiv* 2020:2020.02.06.20020974.

42. Mick E, Kamm J, Pisco AO, et al. Upper airway gene expression differentiates COVID-19 from other acute respiratory illnesses and reveals suppression of innate immune responses by SARS-CoV-2. *medRxiv* 2020.

43. Chua RL, Lukassen S, Trump S, et al. COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis. *Nat Biotechnol* 2020;38:970-9.

44. Iwamoto S, Kumamoto T, Azuma E, et al. The effect of azithromycin on the maturation and function of murine bone marrow-derived dendritic cells. *Clin Exp Immunol* 2011;166:385-92.

45. Sun BB, Maranville JC, Peters JE, et al. Genomic atlas of the human plasma proteome. *Nature* 2018;558:73-9.

46. Ellinghaus D, Degenhardt F, Bujanda L, et al. Genomewide Association Study of Severe Covid-19 with Respiratory Failure. *N Engl J Med* 2020.

47. Newman AM, Steen CB, Liu CL, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. *Nat Biotechnol* 2019;37:773-82.

48. Cai G, Xiao F. SCANNER: A Web Resource for Annotation, Visualization and Sharing of Single Cell RNA-seq Data. *bioRxiv* 2020:2020.01.25.919712.

49. Cancer Genome Atlas Research N, Weinstein JN, Collisson EA, et al. The Cancer Genome Atlas Pan-Cancer analysis project. *Nat Genet* 2013;45:1113-20.

50. Bosse Y, Postma DS, Sin DD, et al. Molecular signature of smoking in human lung tissues. *Cancer Res* 2012;72:3753-63.

51. Seo JS, Ju YS, Lee WC, et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. *Genome Res* 2012;22:2109-19.

52. Landi MT, Dracheva T, Rotunno M, et al. Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. *PLoS One* 2008;3:e1651.

53. Tilley AE, Staudt MR, Salit J, et al. Cigarette Smoking Induces Changes in Airway Epithelial Expression of Genes Associated with Monogenic Lung Disorders. *Am J Respir Crit Care Med* 2016;193:215-7.

54. Strulovici-Barel Y, Omberg L, O'Mahony M, et al. Threshold of biologic responses of the small airway epithelium to low levels of tobacco smoke. *Am J Respir Crit Care Med* 2010;182:1524-32.

55. Tilley AE, Harvey BG, Heguy A, et al. Down-regulation of the notch pathway in human airway epithelium in association with smoking and chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2009;179:457-66.
56. Beane J, Sebastiani P, Liu G, Brody JS, Lenburg ME, Spira A. Reversible and permanent effects of tobacco smoke exposure on airway epithelial gene expression. *Genome Biol* 2007;8:R201.
57. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. *Biostatistics* 2003;4:249-64.
58. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* 2010;26:139-40.
59. Wang X, Park J, Susztak K, Zhang NR, Li M. Bulk tissue cell type deconvolution with multi-subject single-cell expression reference. *Nat Commun* 2019;10:380.
60. Zhang R, Wang Z, Tejera P, et al. Late-onset moderate to severe acute respiratory distress syndrome is associated with shorter survival and higher mortality: a two-stage association study. *Intensive Care Med* 2017;43:399-407.
61. Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 2013;29:15-21.
62. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics* 2014;30:923-30.
63. Garcia-Alcalde F, Okonechnikov K, Carbonell J, et al. Qualimap: evaluating next-generation sequencing alignment data. *Bioinformatics* 2012;28:2678-9.
64. MJ S, L P, RD K, et al. bcbioRNASeq: R package for bcbio RNA-seq analysis [version 2; peer review: 1 approved, 1 approved with reservations]. *F1000Research* 2018;6:1976.
65. Law CW, Chen Y, Shi W, Smyth GK. voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. *Genome Biol* 2014;15:R29.
66. Duclos GE, Teixeira VH, Autissier P, et al. Characterizing smoking-induced transcriptional heterogeneity in the human bronchial epithelium at single-cell resolution. *Sci Adv* 2019;5:eaaw3413.
67. Reyfman PA, Walter JM, Joshi N, et al. Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary Fibrosis. *Am J Respir Crit Care Med* 2019;199:1517-36.
68. Madissoon E, Wilbrey-Clark A, Miragaia RJ, et al. scRNA-seq assessment of the human lung, spleen, and esophagus tissue stability after cold preservation. *Genome Biol* 2019;21:1.
69. Stuart T, Butler A, Hoffman P, et al. Comprehensive Integration of Single-Cell Data. *Cell* 2019;177:1888-902 e21.
70. Lee JS, Park S, Jeong HW, et al. Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. *Sci Immunol* 2020;5.
71. Aran D, Looney AP, Liu L, et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. *Nat Immunol* 2019;20:163-72.
72. Trapnell C, Cacchiarelli D, Grimsby J, et al. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. *Nat Biotechnol* 2014;32:381-6.
73. Selamat SA, Chung BS, Girard L, et al. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. *Genome Res* 2012;22:1197-211.
74. Ringh MV, Hagemann-Jensen M, Needhamsen M, et al. Tobacco smoking induces changes in true DNA methylation, hydroxymethylation and gene expression in bronchoalveolar lavage cells. *EBioMedicine* 2019;46:290-304.
75. Sundar IK, Yin Q, Baier BS, et al. DNA methylation profiling in peripheral lung tissues of smokers and patients with COPD. *Clin Epigenetics* 2017;9:38.
76. Enfield KSS, Marshall EA, Anderson C, et al. Epithelial tumor suppressor ELF3 is a lineage-specific amplified oncogene in lung adenocarcinoma. *Nat Commun* 2019;10:5438.
77. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* 2005;102:15545-50.
78. Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M. KEGG as a reference resource for gene and protein annotation. *Nucleic Acids Res* 2016;44:D457-62.
79. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res* 2003;13:2498-504.
80. Doncheva NT, Morris JH, Gorodkin J, Jensen LJ. Cytoscape StringApp: Network Analysis and Visualization of Proteomics Data. *J Proteome Res* 2019;18:623-32.
81. Cai G, Liang S, Zheng X, Xiao F. Local sequence and sequencing depth dependent accuracy of RNA-seq reads. *BMC Bioinformatics* 2017;18:364.

82. Kim JK, Kolodziejczyk AA, Ilicic T, Teichmann SA, Marioni JC. Characterizing noise structure in single-cell RNA-seq distinguishes genuine from technical stochastic allelic expression. *Nat Commun* 2015;6:8687.
83. Li J, Witten DM, Johnstone IM, Tibshirani R. Normalization, testing, and false discovery rate estimation for RNA-sequencing data. *Biostatistics* 2012;13:523-38.
84. Carpenter B, Gelman A, Hoffman MD, et al. Stan: A Probabilistic Programming Language. 2017 2017;76:32.
85. Kruschke JK. Bayesian estimation supersedes the t test. *J Exp Psychol Gen* 2013;142:573-603.
86. Kamat MA, Blackshaw JA, Young R, et al. PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. *Bioinformatics* 2019;35:4851-3.
87. Pividori M, Rajagopal PS, Barbeira A, et al. PhenomeXcan: Mapping the genome to the phenome through the transcriptome. *Sci Adv* 2020;6.
88. G. TEx Consortium. The Genotype-Tissue Expression (GTEx) project. *Nat Genet* 2013;45:580-5.
89. Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference across the human phenome. *Elife* 2018;7.

Figure

Figure 1. Correlation and variation of SARS-CoV-2 receptors and immune factors in nasopharynx/pharynx samples of SARS-CoV-2 ARIs. (A) Scatter plots of gene expression profiles of SARS-CoV-2 receptor ACE2, immune response activators (CD80, CD83 and CD86), the proportion of active CD4 memory T cells and M1 macrophages in 22 immune cell types, as well as scores from a linear model of 5 immune cell types (active CD4 memory T cells, M1 Mø, mast cells, neutrophils and active DCs). Their associations with viral load are also visualized in scatter plots. The black and red lines are fits of linear model and LOESS, respectively. (B)

Hierarchical clustering and heatmap of SARS-CoV-2 receptors, immune factors and proportions of 5 immune cell types in ARI subsets, including 1 subset with low SARS-CoV-2 load (LoLoad) and 4 subsets with high SARS-CoV-2 load and activated DCs (DC+), activated T or M1 Mø (T/Mø+), activated neutrophils (Neu+) and DC-T/Mø-Neu-. Compared each subset to others, the fold changes and 95% confidence intervals of each feature are shown on the bottom. The size of the squares is proportional to the standard deviation.

Figure 2. The effect of smoking on pulmonary gene expression of three SARS-CoV-2 receptors. (A) Forest plots for the effects of smoking on *CD209* pulmonary gene expression.

The top panel shows a comparison of ever-smokers (including current and former smokers) and nonsmokers, and the bottom panel shows the association of *CD209* gene expression with smoking status (never, former, or current smoker). For each study, pooled effect size, 95% CI and P values were calculated by meta-analysis. The size of the squares is proportional to the weights, which were estimated by the standard “inverse-variance” method for random-effects models in meta-analysis. (B) The expression profiles of *ACE2*, *CD209* and *CLEC4M* genes in airways of ever-smokers and non-smokers. For each gene, detection rate (showed by dot size, larger dot indicates higher detection rate) and expression level (showed by dot color which is status specific, darker indicates higher expression level) are shown in identified cell types. The goblet cell in never smokers in the GSE122960 dataset was shown in grey because only a limited number of cells was detected. Significance: * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$. Red * indicates higher expression and blue * indicates lower expression in ever-smokers compared to never-smokers. (C) The association of lung *CD209* methylation with smoking and gene expression. The left panel shows a forest plot for the effects of smoking on *CD209* related methylation probes in normal lung tissues. For each probe, pooled effect size, 95% CI and P values were calculated by meta-analysis from available studies, including a: TCGA, b: GSE32861, c: GSE133062, d: GSE92511 and e: GSE139032. The right panel shows the correlation between *CD209* gene expression levels and measurements of methylation probes (cg01618851, cg07608333) in normal lung tissues from the GSE32861 study.

Figure 3. The effect of smoking on lung DCs. (A) Forest plots for the effects of smoking on immune cell composition. For each cell type, the left panel shows a comparison of ever-smoker (including current and former smokers) and nonsmoker groups, and the right panel shows the association of the percentage of the cell in 22 immune cells with smoking status (never, former, or current smoker). For each study, the estimated effect size and 95% confidence intervals (CIs) are plotted. The size of the squares is proportional to the weights, which were estimated by the standard “inverse-variance” method for random-effects models in meta-analysis. (B) Violin plots of the expression of functional markers in DCs from two scRNA-seq datasets. Red P values indicates higher expression and blue P values indicates lower expression in ever-smokers compared to never-smokers. (C) Gene expression networks dysregulated in ever-smoker lungs. The color of a node corresponds to the significance of the gene set (red corresponds to positive effect; blue corresponds to negative effect). Node size corresponds to the number of genes within the gene set. Edge weight corresponds to the number of genes found in both connected gene sets. (D) GSEA enrichment scores of KEGG Asthma and DNA replication pathways. The top portion of the plot shows the running Enrichment Score (ES) for the gene set, the middle portion shows the ranks of the members of the gene set in the ranked list of genes transcriptome wide, and the bottom portion shows the value of the ranking metric in ordered dataset.

Figure 4. Gene expression differences of three SARS-Cov-2 receptors in upper airway, lung and blood of healthy and COVID-19 cases. (A) Expression profiles of *ACE2*, *CD209* and *CLEC4M* in cell types identified from four scRNA-seq datasets of nasopharynx/pharynx, BALF

and PBMC samples from COVID-19 patients and healthy controls. For each dataset, the detection rate (showed by dot size, larger dot indicates higher detection rate) and expression level (showed by dot color which is status specific, darker indicates higher expression level) of each receptor in identified cell types are shown. The gd T cell in never smokers in the GSE122960 dataset was shown in grey because only a limited number of cells was detected.

(B) The proportions of DCs, macrophages or monocytes in WBC in samples from each participant. The differences of expression in DCs, monocytes and monocytes were tested in groups. Significance: * $P < 0.05$; ** $P < 0.01$; *** $P < 0.01$. Red * indicates higher expression and blue * indicates lower expression in severe cases compared to mild cases, in severe cases compared to healthy controls, in mild cases compared to healthy controls, in severe cases compared to asymptomatic cases, in mild cases compared to asymptomatic cases, or in asymptomatic cases compared to healthy controls.

A. Lung DCs

B. Blood DCs

C. Lung DCs

Figure 5. Dysregulated gene expression networks in lung and blood with COVID-19. Each node in network is a pie plot showing three comparisons, including mild vs healthy (top right), severe vs healthy (bottom), and severe vs mild (top left). Node size corresponds to the number of genes in dataset within the gene set. Color intensity inner the node corresponds to the significance of the gene set for this dataset (red is for positive effect; blue is for negative effect). Orange outer circles show the overlapping gene sets found in (A) lung DCs and (B) blood DCs, while blue outer circles show the uniquely detected gene sets. Edge weight corresponds to the number of genes found in both connected gene sets. Venn diagrams show the distribution of significant altered genes more than 2 folds detected from three comparisons in each dataset. (C) shows STRING networks of changed genes in lung DCs in severe COVID-19 cases compared to healthy (left) and mild cases (right). The intensity of filling color corresponds to the $\log_2FC$ of the gene (red is for positive effect; blue is for negative effect).

Fig. 6 The expression profiles of functional markers in DCs at three sites. (A) The expression disparity of markers of maturation (CD83), T-cell stimulation molecules (CD40, CD80, CD86) and antigen presentation molecules (HLA-DQA2 and FCER1A) in DCs of COVID-19 cases and healthy controls. 1 upper airway (nasopharynx/pharynx), 1 lung (BALF) and 2 blood (PBMC) scRNA-seq datasets were analyzed. Significance: * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$. Red * indicates higher expression and blue * indicates lower expression in severe cases compared to mild cases, in severe cases compared to healthy controls, in mild cases compared to healthy controls, in severe cases compared to asymptomatic cases, in mild cases compared to asymptomatic cases, or in asymptomatic cases compared to healthy controls. Despite interest, we did not compare COVID-19 nasopharynx/pharynx samples to healthy controls due to the limited detection of DCs ($N = 1$). (B) The dysregulation of gene expression of MHCII and FcRs in APCs at 3 sites with COVID-19. For each gene, the alteration of gene expression in APCs of severe COVID-19 cases compared to mild cases, and that in mild COVID-19 cases compared to healthy controls are visualized in heatmaps. Red indicates upregulation and blue indicates downregulation. The scale corresponds to $\log_2FC$.

Fig. 7 The variation of DC subsets in COVID-19 samples and healthy controls at three sites. (A) DC subsets identified in single-cell transcriptome profiles from COVID-19 mild and severe cases and healthy controls. 1 upper airway (nasopharynx/pharynx), 1 lung (BALF) and 2

blood (PBMC) scRNA-seq datasets were analyzed. (B) The proportions of DC subsets in samples from each participant was shown in the top panel for each dataset. The differences of proportion of each DC subset were tested in groups. Significance: * $P < 0.05$; ** $P < 0.01$. The bottom panel shows gene expression profile of the T-cell stimulation activators (CD83, CD40, CD80, CD86), MHCII and FcRs in subsets in samples with different disease status. Red indicates upregulation and blue indicates downregulation. The scale corresponds to the $\log_2$ (normalized scRNA-seq read count) which was centered and scaled by row. (C) Single-cell trajectory of DCs inferred from scRNA-seq data from BALF and PBMC samples. For each dataset, the right shows ordered cells from COVID-19 mild and severe cases, and healthy controls. The left shows ordered cells labeled with identified cell types.

Supplementary File

Figure S1. The association of SARS-CoV-2 receptors and immune factors with SARS-CoV-2 infection and viral load in nasopharynx/pharynx samples of ARIs.

For each feature, results of comparisons between SARS-CoV-2 ARIs and non-viral ARIs are shown on the left and correlations with SARS-CoV-2 viral load are shown on the right. For each feature, the estimated coefficient and 95% confidence intervals (CIs) are plotted. Significant P values which are less than 0.05 were shown in bold.

Figure S2. Correlation matrix among immune cell composition and the expression of *ACE2*, *CLEC4M* and *CD209* in ARDS and non-ARDS blood samples. Pairwise similarity (Spearman correlation) among the expression of candidate genes and 22 immune cells proportions in ARDS blood samples is shown on the left, and that in non-ARDS blood samples is shown on the right.

Figure S3. The forest plots for the effects of smoking on *ACE2* pulmonary gene expression.

For each cell type, the top panel shows a comparison of ever-smoker (including current and former smokers) and nonsmoker groups, and the bottom panel shows the association of the gene expression with smoking status (never, former, or current smoker). For each study, the estimated effect size and 95% confidence intervals (CIs) are plotted. The size of the squares is proportional to the weights, which were estimated by the standard “inverse-variance” method for random-effects models in meta-analysis.

Figure S4. Clusters of single-cell transcriptomics of bronchial epithelium and lung cells.

For each dataset, the left shows UMAP embedding of single-cell transcriptome profiles from never smokers and current or ever smokers. The right shows identified cell types.

Figure S5. Expression profiles of cell type markers in scRNA-seq data of bronchial epithelium and lung cells.

For each marker, detection rate (showed by dot size, larger dot indicates higher detection rate) and expression level (showed by dot color which is status specific, darker indicates higher expression level) are shown in identified cell types.

Figure S6. The forest plot for the effects of smoking on *ACE2* related methylation probes in normal lung tissues.

For each probe, pooled effect size, 95% CI and P values were calculated by meta-analysis from available studies, including a: TCGA, b: GSE32861, c: GSE133062, d: GSE92511 and e: GSE139032. For each study, the estimated effect size and 95% confidence intervals (CIs) are plotted. The size of the squares is proportional to the weights, which were estimated by the standard “inverse-variance” method for random-effects models in meta-analysis.

Figure S7. The proportion of DCs in WBC of lungs of never and ever smokers. The proportion of DCs were enumerated from the scRNA-seq data of lung samples of each participant recruited in two independent studies.

Nasopharynx/pharynx

BALF

PBMC, Lee et al.

PBMC, Wilk et al.

Figure S8. Clusters of single-cell transcriptomics of nasopharynx/pharynx, BALF and PMBC samples from COVID-19 cases and healthy controls.

For each dataset, the left shows UMAP embedding of single-cell transcriptome profiles from COVID-19 mild and severe cases, and healthy controls. The right shows identified cell types.

PBMC, Lee et al.

Figure S9. The dysregulation of gene expression of MHCII and FcRs in APCs in blood with COVID-19. For each gene, the alteration of gene expression in asymptomatic, mild and severe COVID-19 cases compared to healthy controls are visualized in heatmaps. Red indicates upregulation and blue indicates downregulation. The scale corresponds to log₂FC. The PBMC scRNA-seq dataset of Lee et al. was analyzed.

Figure S10. Expression profiles of DC subset markers in four scRNA-seq datasets of

nasopharynx/pharynx, BALF and PBMC samples from COVID-19 patients and healthy

controls. For each dataset, the detection rate (showed by dot size, larger dot indicates higher

detection rate) and expression level (showed by dot color, darker indicates higher expression

level) of each cell-type marker are shown in identified DC subtypes.

Figure S11. Integrated single-cell transcriptomics of nasopharynx/pharynx, BALF and PMBC samples from COVID-19 cases and healthy controls.

The left shows UMAP embedding of single-cell transcriptome profiles from COVID-19 mild and severe cases, and healthy controls. The right shows identified cell types.

Figure S12. Hierarchical clustering and heatmap of immune cell composition in ARI nasopharynx/pharynx samples from COVID-19 cases and healthy controls. For each cell

type, red indicates relatively higher proportion and blue indicates relatively higher proportion across samples.

nasopharynx/pharynx

Figure S13. Single-cell trajectory of DCs in COVID-19 nasopharynx/pharynx samples. The right shows ordered cells from COVID-19 mild and severe cases. The left shows ordered cells labeled with identified cell types.

Figure S14. Transcriptional bursting profiles in different DC subsets. The changes in burst frequency and burst size of HLA genes (blue) and Cox genes (red) in ANXA1+DC compared to pDC (left) and cDC2 (right) are plotted in $\log_2$ scale.

Figure S15. Correlation of genes *ACE2*, *CLEC4M* and *CD209* in normal lung tissues.

Spearman correlation coefficients for expression of each pair of genes were shown in boxplot.

Table S1. Mendelian Randomization inferred causal effect of plasma expression of ACE2, DC-SIGN and L-SIGN on COVID-19 risk and severity in the European population.

Mendelian Randomization inferred causal effect of plasma expression of ACE2, DC-SIGN and L-SIGN on COVID-19 risk and severity in the European population.												
outcome	exposure	method	nsnp	b	se	pval	Q	Q_df	Q_pval	egger_intercept	se	pval
COVID-19 risk	plasma DC-SIGN expression	MR Egger	3	0.12	0.10	4.49E-01	0.50	1	0.48	0.02	0.06	0.838
		Weighted median	3	0.14	0.05	4.17E-03						
		Inverse variance weighted	3	0.14	0.05	3.39E-03	0.57	2	0.75			
		Simple mode	3	0.11	0.07	2.59E-01						
		Weighted mode	3	0.13	0.05	1.21E-01						
COVID-19 severity		MR Egger	3	0.42	0.18	2.61E-01	2.13	1	0.14	-0.08	0.11	0.600
		Weighted median	3	0.31	0.06	2.21E-07						
		Inverse variance weighted	3	0.30	0.08	5.41E-05	3.26	2	0.20			
		Simple mode	3	0.35	0.13	1.14E-01						
		Weighted mode	3	0.34	0.07	3.60E-02						
COVID-19 risk	plasma ACE2 expression	MR Egger	60	0.38	0.21	8.41E-02	46.39	58	0.86	-0.04	0.03	0.114
		Weighted median	60	0.04	0.07	6.08E-01						
		Inverse variance weighted	60	0.04	0.05	4.05E-01	48.96	59	0.82			
		Simple mode	60	0.04	0.15	8.09E-01						
		Weighted mode	60	0.04	0.16	8.24E-01						
COVID-19 severity		MR Egger	59	0.28	0.26	2.86E-01	57.45	57	0.46	-0.04	0.03	0.285
		Weighted median	59	0.05	0.09	6.08E-01						
		Inverse variance weighted	59	0.01	0.06	9.02E-01	58.63	58	0.45			
		Simple mode	59	0.15	0.22	5.01E-01						
		Weighted mode	59	0.17	0.24	4.70E-01						
COVID-19 risk	plasma L-SIGN expression	Wald ratio	1	0.41	0.23	7.70E-02						
COVID-19 severity		Wald ratio	1	-0.18	0.29	5.42E-01						

Table S2. The top 100 CD209 expression associated traits identified by GWAS.

It is made available under a [CC-BY-NC-ND 4.0 International license](#).

The top 100 CD209 expression associated traits identified by GWAS.															
rsid	hg19_coordinates	hg38_coordinates	a1	a2	phenotype	phenotype_sc	ancestry	effect_size	pvalue						
rs536227604	chr19:7809392	chr19:7744506	T	C	Cause of death: asthma, unspecified	UKBB	European	-0.067	1.00E-11						
rs538085590	chr19:7806977	chr19:7742091	A	G	Benign neoplasm of urinary organs	UKBB	European	-0.001926	2.85E-11						
rs71534255	chr19:7811590	chr19:7746704	A	C	Cause of death: chronic myeloid leukaemia	UKBB	European	0.05117	1.01E-11						
rs536227604	chr19:7809392	chr19:7744506	T	C	Malignant neoplasm of tonsil	UKBB	European	-0.004153	8.42E-11						
rs73493971	chr19:7808679	chr19:7743793	A	G	Self-reported parathyroid hyperplasia or adenoma	UKBB	European	-0.002712	4.40E-09						
rs190601505	chr19:7808683	chr19:7743797	A	G	Self-reported parathyroid hyperplasia or adenoma	UKBB	European	0.002597	9.58E-09						
rs73493971	chr19:7808679	chr19:7743793	A	G	Cause of death: cerebrium, except lobes and ventricles	UKBB	European	-0.0267	1.07E-08						
rs190601505	chr19:7808683	chr19:7743797	A	G	Cause of death: cerebrium, except lobes and ventricles	UKBB	European	0.02613	1.48E-08						
rs185373670	chr19:7807235	chr19:7742349	T	C	Treatment with cinnarizine	UKBB	European	0.003609	2.32E-08						
rs11465395	chr19:7807742	chr19:7742856	C	G	Treatment with maxalt 5mg tablet	UKBB	European	0.00287	2.99E-08						
rs73493973	chr19:7808806	chr19:7743920	A	G	Treatment with maxalt 5mg tablet	UKBB	European	0.002828	3.94E-08						
rs73493968	chr19:7808653	chr19:7743767	T	C	Treatment with maxalt 5mg tablet	UKBB	European	-0.002824	4.09E-08						
rs73493965	chr19:7808506	chr19:7743620	T	C	Treatment with maxalt 5mg tablet	UKBB	European	0.002817	4.22E-08						
rs73493966	chr19:7808543	chr19:7743657	C	G	Treatment with maxalt 5mg tablet	UKBB	European	-0.002818	4.30E-08						
rs114437818	chr19:7808340	chr19:7743454	T	G	Treatment with maxalt 5mg tablet	UKBB	European	-0.002816	4.40E-08						
rs114878389	chr19:7808341	chr19:7743455	A	G	Treatment with maxalt 5mg tablet	UKBB	European	0.002816	4.41E-08						
rs112039104	chr19:7808709	chr19:7743823	A	C	Treatment with maxalt 5mg tablet	UKBB	European	0.002803	4.69E-08						
rs113398041	chr19:7808692	chr19:7743806	T	C	Treatment with maxalt 5mg tablet	UKBB	European	-0.002803	4.71E-08						
rs73493975	chr19:7808840	chr19:7743954	A	G	Treatment with maxalt 5mg tablet	UKBB	European	-0.002798	4.81E-08						
rs61058460	chr19:7809178	chr19:7744292	T	C	Treatment with maxalt 5mg tablet	UKBB	European	-0.00278	5.45E-08						
rs77982873	chr19:7808879	chr19:7743993	T	C	Treatment with maxalt 5mg tablet	UKBB	European	-0.002778	5.49E-08						
rs77377087	chr19:7808882	chr19:7743996	A	T	Treatment with maxalt 5mg tablet	UKBB	European	-0.002778	5.49E-08						
rs61468896	chr19:7809448	chr19:7744562	T	C	Treatment with maxalt 5mg tablet	UKBB	European	0.00278	5.52E-08						
rs17159887	chr19:7809079	chr19:7744193	T	C	Treatment with maxalt 5mg tablet	UKBB	European	-0.002758	6.28E-08						
rs57889796	chr19:7809378	chr19:7744492	T	C	Treatment with maxalt 5mg tablet	UKBB	European	-0.002753	6.56E-08						
rs57668221	chr19:7809116	chr19:7744230	C	G	Treatment with maxalt 5mg tablet	UKBB	European	-0.002746	6.91E-08						
rs78866372	chr19:7809013	chr19:7744127	A	G	Cause of death: cerebral infarction, unspecified	UKBB	European	0.0363	7.18E-08						
rs185373670	chr19:7807235	chr19:7742349	T	C	Malignant neoplasm of other and unspecified parts of tongue	UKBB	European	0.002736	9.50E-08						
rs111716431	chr19:7808465	chr19:7743579	A	G	Treatment with maxalt 5mg tablet	UKBB	European	0.002688	9.96E-08						
rs536227604	chr19:7809392	chr19:7744506	T	C	Self-reported giant cell or temporal arteritis	UKBB	European	-0.002948	2.96E-07						
rs185373670	chr19:7807235	chr19:7742349	T	C	Enthesopathies of lower limb, excluding foot	UKBB	European	0.003231	3.40E-07						
rs538085590	chr19:7806977	chr19:7742091	A	G	Cause of death: vascular disorder of intestine, unspecified	UKBB	European	-0.04267	4.74E-07						
rs11465411	chr19:7806077	chr19:7741191	A	G	Cause of death: inquest adjourned death	UKBB	European	-0.00857	8.45E-07						
rs11465410	chr19:7806079	chr19:7741193	T	C	Cause of death: inquest adjourned death	UKBB	European	-0.008542	8.85E-07						
rs111716431	chr19:7808465	chr19:7743579	A	G	Cause of death: urinary tract infection, site not specified	UKBB	European	0.03359	9.40E-07						
rs185373670	chr19:7807235	chr19:7742349	T	C	Treatment with ftyobol orange s or f granules	UKBB	European	0.006133	9.52E-07						
rs71534255	chr19:7811590	chr19:7746704	A	C	Cause of death: sigmoid colon	UKBB	European	0.08674	1.09E-06						
rs11465409	chr19:7806086	chr19:7741200	A	G	Cause of death: inquest adjourned death	UKBB	European	0.008424	1.11E-06						
rs71534255	chr19:7811590	chr19:7746704	A	C	Treatment with metrogel 0.75% gel	UKBB	European	0.002912	1.11E-06						
rs11465412	chr19:7806070	chr19:7741184	A	G	Cause of death: inquest adjourned death	UKBB	European	0.008289	1.25E-06						
rs73493971	chr19:7808679	chr19:7743793	A	G	Treatment with cyclizine	UKBB	European	-0.0026	1.26E-06						
rs185373670	chr19:7807235	chr19:7742349	T	C	Cause of death: secondary malignant neoplasm of retroperitoneum	UKBB	European	0.02824	1.65E-06						
rs114878389	chr19:7808341	chr19:7743455	A	G	Cause of death: cerebrium, except lobes and ventricles	UKBB	European	0.01839	2.39E-06						
rs114437818	chr19:7808340	chr19:7743454	T	G	Cause of death: cerebrium, except lobes and ventricles	UKBB	European	-0.01838	2.40E-06						
rs11465395	chr19:7807742	chr19:7742856	C	G	Cause of death: cerebrium, except lobes and ventricles	UKBB	European	0.01834	2.41E-06						
rs73493968	chr19:7808653	chr19:7743767	T	C	Cause of death: cerebrium, except lobes and ventricles	UKBB	European	-0.01824	2.62E-06						
rs61468896	chr19:7809448	chr19:7744562	T	C	Cause of death: cerebrium, except lobes and ventricles	UKBB	European	0.01821	2.67E-06						
rs73493966	chr19:7808543	chr19:7743657	C	G	Cause of death: cerebrium, except lobes and ventricles	UKBB	European	-0.0182	2.69E-06						
rs73493965	chr19:7808506	chr19:7743620	T	C	Cause of death: cerebrium, except lobes and ventricles	UKBB	European	0.0182	2.69E-06						
rs73493973	chr19:7808806	chr19:7743920	A	G	Cause of death: cerebrium, except lobes and ventricles	UKBB	European	0.01817	2.73E-06						
rs112039104	chr19:7808709	chr19:7743823	A	C	Cause of death: cerebrium, except lobes and ventricles	UKBB	European	0.01814	2.80E-06						
rs73493975	chr19:7808840	chr19:7743954	A	G	Cause of death: cerebrium, except lobes and ventricles	UKBB	European	-0.01812	2.82E-06						
rs113398041	chr19:7808692	chr19:7743806	T	C	Cause of death: cerebrium, except lobes and ventricles	UKBB	European	-0.01812	2.83E-06						
rs61058460	chr19:7809178	chr19:7744292	T	C	Cause of death: cerebrium, except lobes and ventricles	UKBB	European	-0.01811	2.85E-06						
rs77982873	chr19:7808879	chr19:7743993	T	C	Cause of death: cerebrium, except lobes and ventricles	UKBB	European	-0.01797	3.13E-06						
rs77377087	chr19:7808882	chr19:7743996	A	T	Cause of death: cerebrium, except lobes and ventricles	UKBB	European	-0.01797	3.13E-06						
rs17159887	chr19:7809079	chr19:7744193	T	C	Cause of death: cerebrium, except lobes and ventricles	UKBB	European	-0.01796	3.15E-06						
rs57668221	chr19:7809116	chr19:7744230	C	G	Cause of death: cerebrium, except lobes and ventricles	UKBB	European	-0.01795	3.17E-06						
rs57889796	chr19:7809378	chr19:7744492	T	C	Cause of death: cerebrium, except lobes and ventricles	UKBB	European	-0.01795	3.17E-06						
rs11465395	chr19:7807742	chr19:7742856	C	G	Other disorders of ear	UKBB	European	0.001684	3.54E-06						
rs71534255	chr19:7811590	chr19:7746704	A	C	Cause of death: cardiomegaly	UKBB	European	0.05203	3.98E-06						
rs185373670	chr19:7807235	chr19:7742349	T	C	Treatment with indoramin	UKBB	European	0.002071	4.28E-06						
rs73493968	chr19:7808653	chr19:7743767	T	C	Other disorders of ear	UKBB	European	-0.001659	4.33E-06						
rs73493973	chr19:7808806	chr19:7743920	A	G	Other disorders of ear	UKBB	European	0.001658	4.33E-06						
rs73493966	chr19:7808543	chr19:7743657	C	G	Other disorders of ear	UKBB	European	-0.001658	4.34E-06						
rs111716431	chr19:7808465	chr19:7743579	A	G	Self-reported parathyroid hyperplasia or adenoma	UKBB	European	0.001617	4.34E-06						
rs538085590	chr19:7806977	chr19:7742091	A	G	Diabetes mellitus in pregnancy	UKBB	European	-0.001404	4.38E-06						
rs114437818	chr19:7808340	chr19:7743454	T	G	Other disorders of ear	UKBB	European	-0.001655	4.50E-06						
rs114878389	chr19:7808341	chr19:7743455	A	G	Other disorders of ear	UKBB	European	0.001655	4.50E-06						
rs73493965	chr19:7808506	chr19:7743920	T	C	Other disorders of ear	UKBB	European	0.001653	4.52E-06						
rs112039104	chr19:7808709	chr19:7743823	A	C	Other disorders of ear	UKBB	European	0.001647	4.72E-06						
rs113398041	chr19:7808692	chr19:7743806	T	C	Other disorders of ear	UKBB	European	-0.001647	4.73E-06						
rs73493975	chr19:7808840	chr19:7743954	A	G	Other disorders of ear	UKBB	European	-0.001642	4.95E-06						
rs61058460	chr19:7809178	chr19:7744292	T	C	Other disorders of ear	UKBB	European	-0.001633	5.32E-06						
rs61468896	chr19:7809448	chr19:7744562	T	C	Other disorders of ear	UKBB	European	0.001632	5.37E-06						
rs77982873	chr19:7808879	chr19:7743993	T	C	Other disorders of ear	UKBB	European	-0.001631	5.39E-06						
rs77377087	chr19:7808882	chr19:7743996	A	T	Other disorders of ear	UKBB	European	-0.001631	5.39E-06						
rs11465408	chr19:7806154	chr19:7741268	A	G	Cause of death: inquest adjourned death	UKBB	European	0.007154	5.44E-06						
rs17159887	chr19:7809079	chr19:7744193	T	C	Other disorders of ear	UKBB	European	-0.00162	5.89E-06						
rs57889796	chr19:7809378	chr19:7744492	T	C	Other disorders of ear	UKBB	European	-0.001617	5.99E-06						
rs73493971	chr19:7808679	chr19:7743793	A	G	Cause of death: bladder, unspecified	UKBB	European	-0.08438	6.11E-06						
rs111716431	chr19:7808465	chr19:7743579	A	G	Cause of death: cerebrium, except lobes and ventricles	UKBB	European	0.01699	6.11E-06						
rs11465411	chr19:7806077	chr19:7741191	A	G	Other surgical follow-up care	UKBB	European	-0.001327	6.20E-06						
rs57668221	chr19:7809116	chr19:7744230	C	G	Other disorders of ear	UKBB	European	-0.001614	6.21E-06						
rs11465410	chr19:7806079	chr19:7741193	T	C	Other surgical follow-up care	UKBB	European	-0.001323	6.49E-06						
rs190601505	chr19:7808683	chr19:7743797	A	G	Cause of death: bladder, unspecified	UKBB	European	0.08248	7.70E-06						
rs11465395	chr19:7807742	chr19:7742856	C	G	Self-reported parathyroid hyperplasia or adenoma	UKBB	European	0.001615	7.77E-06						
rs111716431	chr19:7808465	chr19:7743579	A	G	Other disorders of ear	UKBB	European	0.001582	7.84E-06						
rs73493973	chr19:7808806	chr19:7743920	A	G	Self-reported parathyroid hyperplasia or adenoma	UKBB	European	0.001596	8.78E-06						
rs73493968	chr19:7808653	chr19:7743767	T	C	Self-reported parathyroid hyperplasia or adenoma	UKBB	European	-0.001594	8.97E-06						
rs71534255	chr19:7811590	chr19:7746704	A	C	Other acquired deformities of musculoskeletal system and cor	UKBB	European	0.00401	9.36E-06						
rs73493966	chr19:7808543	chr19:7743657	C	G	Self-reported parathyroid hyperplasia or adenoma	UKBB	European	-0.001589	9.46E-06						
rs536227604	chr19:7809392	chr19:7744506	T	C	Cause of death: vascular disorder of intestine, unspecified	UKBB	European	-0.06488	9.70E-06						
rs112039104	chr19:7808709	chr19:7743823	A	C	Self-reported parathyroid hyperplasia or adenoma	UKBB	European	0.001583	9.77E-06						
rs113398041	chr19:7808692	chr19:7743806	T	C	Self-reported parathyroid hyperplasia or adenoma	UKBB	European	-0.001583	9.80E-06						
rs113836492	chr19:7810011	chr19:7745125	A	G	Cause of death: thoracic aortic aneurysm, ruptured	UKBB	European	0.01089	9.81E-06						
rs73493975	chr19:7808840	chr19:7743954	A	G	Self-reported parathyroid hyperplasia or adenoma	UKBB	European	-0.001579	9.97E-06						

It is made available under a [CC-BY-NC-ND 4.0 International license](#).

Table S3. The top 100 CD209 lung expression associated traits identified by PheWAS.

The top 100 CD209 lung expression associated traits identified by PheWAS.				
phenotype	phenotype_source	zscore	effect_size	pvalue
Neutrophil percentage	UK Biobank	-4.159	-0.604	3.20E-05
Neutrophil count	UK Biobank	-4.108	-0.100	4.00E-05
Diagnoses - main ICD10: L92 Granulomatous disorders of skin and subcutaneous tissue	UK Biobank	-3.840	-0.002	1.23E-04
Granulomatous disorders of skin and subcutaneous tissue	UK Biobank	-3.840	-0.002	1.23E-04
Granulocyte Count	Astle_et_al_2016	-3.822		1.32E-04
Manic/hyper symptoms: I was more creative or had more ideas than usual	UK Biobank	-3.819	-0.081	1.34E-04
Sum Neutrophil Eosinophil Count	Astle_et_al_2016	-3.745		1.80E-04
Lymphocyte percentage	UK Biobank	3.617	0.455	2.98E-04
Sum Basophil Neutrophil Count	Astle_et_al_2016	-3.556		3.77E-04
Myeloid White Cell Count	Astle_et_al_2016	-3.534		4.09E-04
Neutrophil Count	Astle_et_al_2016	-3.468		5.24E-04
Duration of fitness test	UK Biobank	3.400	0.102	6.74E-04
Diagnoses - main ICD10: Z45 Adjustment and management of implanted device	UK Biobank	3.391	0.005	6.97E-04
Impact on normal roles during worst period of anxiety	UK Biobank	-3.390	-0.169	6.99E-04
White Blood Cell Count	Astle_et_al_2016	-3.342		8.32E-04
Monocyte percentage	UK Biobank	3.231	0.149	1.24E-03
Long-standing illness, disability or infirmity	UK Biobank	-3.194	-0.026	1.40E-03
Recent feelings of tiredness or low energy	UK Biobank	-3.191	-0.077	1.42E-03
Treatment/medication code: amoxicillin (20003_1141180226)	UK Biobank	-3.148	-0.002	1.64E-03
Thoughts of death during worst depression	UK Biobank	-3.138	-0.064	1.70E-03
Non-cancer illness code, self-reported: pleurisy	UK Biobank	-3.109	-0.003	1.88E-03
Other disorders involving the immune mechanism, not elsewhere classified	UK Biobank	-3.020	-0.001	2.53E-03
Stenosis and insufficiency of lacrimal passages	UK Biobank	2.995	0.002	2.75E-03
White blood cell (leukocyte) count	UK Biobank	-2.968	-0.105	3.00E-03
Diagnoses - main ICD10: D89 Other disorders involving the immune mechanism, not elsewhere classified	UK Biobank	-2.964	-0.001	3.03E-03
Diagnoses - main ICD10: D09 Carcinoma in situ of other and unspecified sites	UK Biobank	-2.960	-0.001	3.08E-03
Treatment/medication code: diprosalic ointment (20003_1140882618)	UK Biobank	2.944	0.001	3.24E-03
Never eat eggs, dairy, wheat, sugar: Wheat products	UK Biobank	-2.913	-0.008	3.58E-03
Hospital episode type: General episode	UK Biobank	-2.912	-0.022	3.60E-03
Spondylolisthesis/Spondylolysis	UK Biobank	-2.887	-0.002	3.89E-03
Diagnoses - main ICD10: C49 Malignant neoplasm of other connective and soft tissue	UK Biobank	-2.867	-0.001	4.15E-03
Diagnoses - main ICD10: M43 Other deforming dorsopathies	UK Biobank	-2.864	-0.002	4.18E-03
Job coding: educational assistant, classroom assistant, special needs helper (22601_61243409)	UK Biobank	-2.859	-0.015	4.25E-03
Job coding: credit controller/supervisor (22601_41213252)	UK Biobank	2.838	0.005	4.54E-03
Length of time at current address	UK Biobank	2.824	0.530	4.74E-03
Diagnoses - main ICD10: S43 Dislocation, sprain and strain of joints and ligaments of shoulder girdle	UK Biobank	-2.795	-0.001	5.19E-03
Treatment/medication code: vitamin b6 preparation (20003_1140909874)	UK Biobank	-2.788	-0.002	5.31E-03
Destinations on discharge from hospital (recorded): Usual Place of residence	UK Biobank	-2.787	-0.023	5.32E-03
Types of transport used (excluding work): Walk	UK Biobank	-2.778	-0.024	5.47E-03
Leg fat percentage (right)	UK Biobank	2.775	0.262	5.53E-03
Traumatic subarachnoid haemorrhage	UK Biobank	-2.774	-0.001	5.53E-03
Non-cancer illness code, self-reported: osteopenia	UK Biobank	-2.760	-0.002	5.78E-03
Astigmatism angle (left)	UK Biobank	-2.755	-5.147	5.87E-03
Treatment/medication code: frusemide (20003_1140866116)	UK Biobank	-2.729	-0.002	6.34E-03
ECG, load	UK Biobank	2.725	1.935	6.43E-03
Sum Eosinophil Basophil Count	Astle_et_al_2016	-2.706		6.81E-03
#Deforming dorsopathies	UK Biobank	-2.674	-0.002	7.50E-03
Loud music exposure frequency	UK Biobank	-2.668	-0.057	7.63E-03
Treatment/medication code: persantin 25mg tablet (20003_1140861780)	UK Biobank	2.667	0.001	7.65E-03
ECG, phase time	UK Biobank	2.656	5.040	7.92E-03
Treatment/medication code: vesicare 5mg tablet (20003_1141200384)	UK Biobank	2.649	0.001	8.08E-03
Job SOC coding: Vehicle body builders and repairers	UK Biobank	-2.648	-0.004	8.11E-03
Difficulty concentrating during worst depression	UK Biobank	-2.645	-0.046	8.18E-03
Other and unspecified granulomatous disorders of skin and subcutaneous tissue	UK Biobank	-2.639	-0.001	8.32E-03
Job coding: civil service executive officer, revenue/tax executive or officer, fraud inspector or officer, job centre adviser (22601_41113204)	UK Biobank	-2.632	-0.017	8.49E-03
Treatment/medication code: vascalpha 5mg m/r tablet (20003_1141190160)	UK Biobank	2.616	0.001	8.89E-03
Job SOC coding: Civil Service executive officers	UK Biobank	-2.611	-0.017	9.04E-03
Mouth/teeth dental problems: Mouth ulcers	UK Biobank	-2.603	-0.014	9.24E-03
Diagnoses - main ICD10: E86 Volume depletion	UK Biobank	2.599	0.001	9.35E-03
Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified	UK Biobank	2.594	0.008	9.48E-03
Non-cancer illness code, self-reported: insomnia	UK Biobank	-2.568	-0.001	1.02E-02
Activities undertaken to treat depression: Talking therapies, such as psychotherapy, counselling, group therapy or CBT	UK Biobank	-2.567	-0.031	1.03E-02
Job SOC coding: Educational assistants	UK Biobank	-2.550	-0.014	1.08E-02
Other and unspecified disorders of skin and subcutaneous tissue	UK Biobank	-2.545	-0.004	1.09E-02
Multiple worries during worst period of anxiety	UK Biobank	-2.528	-0.059	1.15E-02
Age at death	UK Biobank	2.526	0.516	1.15E-02
Sensitivity / hurt feelings	UK Biobank	-2.522	-0.021	1.17E-02
Time spent doing vigorous physical activity	UK Biobank	-2.521	-0.159	1.17E-02
Seen doctor (GP) for nerves, anxiety, tension or depression	UK Biobank	-2.520	-0.020	1.17E-02
Diagnoses - main ICD10: N90 Other noninflammatory disorders of vulva and perineum	UK Biobank	-2.520	-0.002	1.17E-02
Non-cancer illness code, self-reported: labyrinthitis	UK Biobank	-2.515	-0.001	1.19E-02
Job SOC coding: Upholsterers	UK Biobank	2.512	0.003	1.20E-02
Maximum workload during fitness test	UK Biobank	2.503	3.244	1.23E-02
Diagnoses - main ICD10: N32 Other disorders of bladder	UK Biobank	-2.495	-0.005	1.26E-02
Number of trend entries	UK Biobank	2.491	2.562	1.27E-02
Job SOC coding: Textile process operatives	UK Biobank	-2.483	-0.005	1.30E-02
Leg fat percentage (left)	UK Biobank	2.481	0.223	1.31E-02
Diseases of the musculoskeletal system and connective tissue	UK Biobank	-2.480	-0.017	1.31E-02
Fibromyalgia related co-morbidities	UK Biobank	-2.472	-0.003	1.34E-02
Treatment/medication code: omacor 1g capsule (20003_1141181868)	UK Biobank	-2.469	-0.002	1.35E-02
Depression possibly related to stressful or traumatic event	UK Biobank	-2.455	-0.043	1.41E-02
Treatment/medication code: salbutamol 100micrograms spacerhaler (20003_1140926606)	UK Biobank	2.451	0.003	1.43E-02
Eosinophil Count	Astle_et_al_2016	-2.444		1.45E-02
Hypergammaglobulinemia, unspecified	UK Biobank	-2.444	-0.001	1.45E-02
Diagnoses - main ICD10: K11 Diseases of salivary glands	UK Biobank	-2.435	-0.002	1.49E-02
Other disorders of skin and subcutaneous tissue, not elsewhere classified	UK Biobank	-2.420	-0.004	1.55E-02
Diagnoses - main ICD10: L98 Other disorders of skin and subcutaneous tissue, not elsewhere classified	UK Biobank	-2.420	-0.004	1.55E-02
Ankle spacing width	UK Biobank	2.418	0.216	1.56E-02
Diagnoses - main ICD10: C67 Malignant neoplasm of bladder	UK Biobank	-2.410	-0.003	1.60E-02
Job coding: taxi or cab driver, chauffeur, hearse driver (22601_82142611)	UK Biobank	2.409	0.004	1.60E-02
Illnesses of father: Stroke	UK Biobank	2.406	0.016	1.62E-02
Basophil count	UK Biobank	-2.405	-0.035	1.62E-02
Job coding: textile machine operator, assembler, spinner, foreman (22601_81132710)	UK Biobank	-2.399	-0.004	1.65E-02
Job SOC coding: Taxi, cab drivers and chauffeurs	UK Biobank	2.397	0.004	1.65E-02
Diagnoses - main ICD10: J38 Diseases of vocal cords and larynx, not elsewhere classified	UK Biobank	-2.395	-0.002	1.66E-02
Job coding: upholsterer, coach trimmer, curtain maker, mattress maker (22601_54122878)	UK Biobank	2.387	0.003	1.70E-02
Other serious medical condition/disability diagnosed by doctor	UK Biobank	-2.385	-0.017	1.71E-02
Used an inhaler for chest within last hour	UK Biobank	-2.376	-0.004	1.75E-02
Treatment/medication code: kapake tablet (20003_1140864070)	UK Biobank	2.367	0.001	1.79E-02
Birth Weight	EGG	-2.366		1.80E-02

Table S4. Mendelian Randomization inferred causal effect of plasma expression of DC-SIGN on cell count and percentage.

Mendelian Randomization inferred causal effect of plasma expression of DC-SIGN on cell count and percentage.						
outcome	exposure	method	nsnp	b	se	pval
White blood cell (leukocyte) count id:ukb-d-30000_irnt	plasma DC-SIGN expression	Inverse variance weighted	3	-0.0305717	0.00284163	5.40E-27
Neutrophil count id:ukb-d-30140_irnt	plasma DC-SIGN expression	Inverse variance weighted	3	-0.0274776	0.00332404	1.38E-16
Red blood cell count id:ieu-a-275	plasma DC-SIGN expression	Inverse variance weighted	3	-0.0140248	0.00271122	2.31E-07
Lymphocyte percentage id:ukb-d-30180_irnt	plasma DC-SIGN expression	Inverse variance weighted	3	0.01685935	0.00417076	5.29E-05
Granulocyte count id:ebi-a-GCST004614	plasma DC-SIGN expression	Inverse variance weighted	2	-0.0422213	0.01085916	0.00010104
Sum neutrophil eosinophil counts id:ebi-a-GCST004613	plasma DC-SIGN expression	Inverse variance weighted	2	-0.0412766	0.01084251	0.00014071
Myeloid white cell count id:ebi-a-GCST004626	plasma DC-SIGN expression	Inverse variance weighted	2	-0.0397515	0.01088796	0.00026126
Sum basophil neutrophil counts id:ebi-a-GCST004620	plasma DC-SIGN expression	Inverse variance weighted	2	-0.0389864	0.01085165	0.00032731
Granulocyte percentage of myeloid white cells id:ebi-a-GCST004608	plasma DC-SIGN expression	Inverse variance weighted	2	-0.0385173	0.01080265	0.0003631
Neutrophil count id:ebi-a-GCST004629	plasma DC-SIGN expression	Inverse variance weighted	2	-0.03781	0.01083361	0.00048291
White blood cell count id:ebi-a-GCST004610	plasma DC-SIGN expression	Inverse variance weighted	2	-0.0369582	0.01084099	0.00065174
Lymphocyte count id:ukb-d-30120_irnt	plasma DC-SIGN expression	Inverse variance weighted	3	-0.0109447	0.00348627	0.0016931
Red blood cell (erythrocyte) count id:ukb-d-30010_irnt	plasma DC-SIGN expression	Inverse variance weighted	3	-0.0304825	0.00983767	0.00194473
Monocyte percentage of white cells id:ebi-a-GCST004609	plasma DC-SIGN expression	Inverse variance weighted	2	0.03090055	0.01174645	0.00852271
Eosinophil counts id:ebi-a-GCST004606	plasma DC-SIGN expression	Inverse variance weighted	2	-0.0280988	0.01078562	0.0091817
Monocyte count id:ukb-d-30130_irnt	plasma DC-SIGN expression	Inverse variance weighted	3	-0.0422452	0.01664811	0.01116349
Neutrophil percentage of white cells id:ebi-a-GCST004633	plasma DC-SIGN expression	Inverse variance weighted	2	-0.024563	0.01079162	0.02283885
Eosinophil percentage id:ukb-d-30210_irnt	plasma DC-SIGN expression	Inverse variance weighted	3	-0.0092451	0.00411516	0.0246658
Lymphocyte percentage of white cells id:ebi-a-GCST004632	plasma DC-SIGN expression	Inverse variance weighted	2	0.02273265	0.01077233	0.03483415

Acknowledgments

This work was supported by University of South Carolina COVID-19 research initiative (G.C.).

Author Contributions

Conceptualization, G.C. and F.X.; Methodology, G.C. and F.X.; Software/Data Analysis, G.C., Y.B., M.D., F.Q., X.Y., X.L., X.C.; Investigation, G.C., H.A., M.A., X.Z., J.Z., C.Y., C.C., M.N., P.N., D.C., M.W., C.A. and F.X.; Writing – Original Draft, G.C., X.Z., J.Z. and F.X.; Writing – Review & Editing, G.C., Y.B., M.D., H.A., F.Q., X.Y., X.L., M.A., X.Z., J.Z., X.C., C.Y., C.C., M.N., P.N., D.C., M.W., C.A. and F.X.

Declaration of Interests

The authors declare no competing interests.